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Vascular risk factors and conditions 
have been associated with dementia 
and Alzheimer’s disease (AD), but the 
mechanisms are not fully understood. 
Because typical Alzheimer and 
cerebrovascular pathologies can 
develop long before dementia onset, 
a life-course perspective is needed to 
investigate risk factors. The present 
thesis focused on the effects of 
vascular risk factors and conditions 
during three decades from midlife 
to late-life on dementia-related 
structural brain changes on MRI in 
late-life.
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ABSTRACT 
 
Cardiovascular risk factors and conditions have been associated with an increased risk of 
dementia, but the mechanisms and mediating pathways are not fully understood. The present 
thesis focuses on the long-term relationships between blood pressure, body mass index (BMI), 
cholesterol, coronary heart disease (CHD) and dementia-related structural brain changes on 
magnetic resonance images (MRI). An additional aim was to investigate the associations 
between midlife CAIDE Dementia Risk Score and brain changes on MRI. 
   The thesis is based on the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) study. 
CAIDE participants were derived from random, population-based samples surveyed in 1972, 
1977, 1982 or 1987 (midlife examination). They were re-examined 21 years later in 1998, and 
again in 2005-2008. The MRI populations included a group of 112 participants in 1998 re-
examination, and a different group of 69 participants in 2005-2008 re-examination. Robust 
visual rating and novel automatic segmentation methods were used to determine structural 
brain changes on MRI. 
    Midlife and long-standing hypertension and overweight/obesity were associated with more 
severe white matter lesions (WML) at older ages. Midlife hypertension was also related to 
thinner cerebral cortex 30 years later. Declining blood pressure from midlife to late-life was 
related to more severe WML, and to thinner cortex in regions involved in blood pressure 
regulation. Long-term CHD was associated with lower total gray matter volume and thinner 
cortex, and this relationship was influenced by changes in blood pressure over time. CAIDE 
Dementia Risk Score in midlife was most consistently associated with WML later in life, and a 
relationship with medial temporal lobe atrophy (MTA) was observed in individuals with 
longer follow-up times. 
    These results indicate that early and sustained control of vascular risk factors may lead to a 
lower likelihood of cerebrovascular or neurodegenerative brain changes as the individual 
ages. It is also important to consider the possibility of a potential bidirectional association 
between vascular factors and brain changes. The CAIDE Dementia Risk Score, a simple and 
readily available tool for estimating dementia risk, seems to indicate even increased risk of 
developing cerebrovascular or typical Alzheimer pathologies. 
 
National Library of Medical Classification: WL 358.5, WL 355, WL 307, WG 142, WL 141.5.M2 
Medical Subjects Headings: Dementia; Mild Cognitive Impairment; Blood Pressure; Body Mass Index; 
Cardiovascular Diseases; Risk Factors; Magnetic Resonance Imaging; Brain/pathology; Cerebral 
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TIIVISTELMÄ 
 
Sydän- ja verisuonitaudit sekä niiden riskitekijät lisäävät riskiä sairastua dementiaan, mutta 
taustalla olevat mekanismit ovat osittain epäselviä. Tämän väitöskirjatyön tavoitteena oli 
selvittää verenpaineen, painoindeksin, kokonaiskolesterolin ja sepelvaltimotaudin 
pitkäaikaista yhteyttä magneettikuvissa (MRI) nähtäviin dementiaan liittyviin rakenteellisiin 
aivomuutoksiin. Lisäksi väitöskirjassa tarkasteltiin keski-iän CAIDE dementia-riskimittarin 
yhteyttä aivojen rakenteellisiin muutoksiin myöhemmällä iällä. 
    Väitöskirja pohjautuu suomalaiseen Kardiovaskulaariset riskitekijät, ikääntyminen ja 
dementia (CAIDE) tutkimukseen. CAIDE-tutkimukseen osallistujat valittiin satunnaisesti 
Pohjois-Karjala projektin ja FINMONICA-tutkimuksen vuosien 1972, 1977, 1982 ja 1987 
neljästä itsenäisestä väestöotannasta. Valitut henkilöt tutkittiin uudelleen 21 vuotta 
myöhemmin vuonna 1998 ja toisen kerran vuosina 2005-2008. Vuoden 1998 MRI-aineiston 
muodosti 112 tutkimushenkilöä ja vuosien 2005-2008 MRI-aineiston muodosti toiset 69 
henkilöä. Aivojen rakenteelliset muutokset magneettikuvissa arvioitiin perinteisiä visuaalisia 
sekä uudempia automaattisia menetelmiä käyttäen. 
    Keski-iässä sekä seurannassa koholla ollut verenpaine ja ylipaino/lihavuus olivat 
yhteydessä aivojen valkean aineen muutoksiin myöhemmällä iällä. Keski-iän kohonnut 
verenpaine oli myös yhteydessä aivojen kuorikerroksen ohentumiseen 30 vuotta myöhemmin. 
Verenpaineen lasku seurannan aikana lisäsi riskiä valkean aineen muutoksille sekä 
kuorikerroksen ohentumiselle erityisesti verenpaineen säätelyyn vaikuttavilla alueilla. 
Pitkäkestoinen sepelvaltimotauti oli yhteydessä harmaan aineen sekä aivojen kuorikerroksen 
pienentymiseen ja verenpaineen muutoksilla oli merkittävä vaikutus tähän yhteyteen. Keski-
iän CAIDE dementia-riskimittarin pisteytys oli yhteydessä valkean aineen sekä sisemmän 
ohimolohkon muutoksiin myöhemmällä iällä. 
    Sydän- ja verisuonisairauksien riskitekijöiden hoidolla voidaan mahdollisesti vaikuttaa 
aivoverisuonisairauksien ja aivohermojen rappeutumiseen liittyvien aivomuutosten 
kehittymiseen. Yksinkertaista ja helposti saatavilla olevaa CAIDE dementia-riskimittaria 
voidaan käyttää myös aivomuutosten riskiä arvioidessa. 
 
Luokitus: WL 358.5, WL 355, WL 307, WG 142, WL 141.5.M2 
Yleinen suomalainen asiasanasto: dementia; muistihäiriöt; verenpaine; painoindeksi; sepelvaltimotauti; 
riskitekijät; magneettitutkimus; aivokuori 
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 1 Introduction 
 
Cognitive impairment is a common condition in individuals at older ages, and it can 
progress over time ultimately to extremely disabling dementia. Alzheimer disease 
(AD), the main cause of dementia, has reached epidemic proportions, being 
responsible for an enormous human, social, and economic burden. In 2010, 35 
million persons worldwide were estimated to suffer from dementia, with the 
prevalence being predicted to at least double or even triple before 2040 (Prince et al., 
2013). The annual worldwide cost of dementia has been estimated to be around 600 
billion dollars (Wimo et al., 2013). 
    The 2014 G8 Dementia Summit identified dementia prevention as a major public 
health priority. It has been estimated that as many as half of AD/dementia cases are 
attributable to modifiable vascular and lifestyle-related risk factors, creating a clear 
window of opportunity for prevention (Barnes and Yaffe, 2011). The pathogenesis of 
AD has still not been fully elucidated, but it has become clear that the etiology of the 
sporadic form of the disease is complex and multifactorial. Several types of 
dementia-related pathologies (e.g. neurodegenerative, cerebrovascular) can share 
risk factors, and can be present simultaneously and interact with one another as the 
individual ages (Kivipelto et al., 2009). These aspects need to be taken into account in 
prevention studies. 
    New diagnostic criteria have shifted the focus from dementia to pre-dementia 
disease stages, and biomarkers (e.g. neuroimaging, laboratory) have become more 
important in the diagnosis of AD. This shift towards earlier disease stages has also 
led to an increased emphasis on the prevention of cognitive decline and dementia. 
Several multifactorial intervention trials have been launched during the past few 
years (Richard et al., 2012a). 
    The present thesis focuses on the effects of vascular risk factors and conditions 
(hypertension, overweight/obesity, hypercholesterolemia, coronary heart disease) 
from midlife to late-life on dementia-related structural brain changes evaluated by 
MRI in older aged individuals. Since Alzheimer and cerebrovascular pathologies can 
take a long time to develop before the onset of dementia, a life-course perspective is 
needed to identify risk factors. In addition, vascular factor levels can change over 
time, and it is not clear how different patterns of change from midlife to late-life are 
related to MRI findings in late-life. The Cardiovascular Risk Factors, Aging and 
Dementia (CAIDE) study in Finland is a population-based study with information 
available on vascular risk factors from midlife until as long as three decades later. 
The CAIDE Dementia Risk Score is a validated tool for estimating dementia risk 
based on a midlife profile including vascular factors (Kivipelto et al. 2006). It is 
important to clarify if the risk score has any relation to MRI findings in addition to 
its dementia prediction ability. The studies in this thesis use several methods for 
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MRI analysis, providing information on both neurodegenerative and 
cerebrovascular pathologies. 
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2 Review of the literature 
 
2.1 DEMENTIA, ALZHEIMER’S DISEASE AND VASCULAR 
COGNITIVE IMPAIRMENT 
2.1.1 Diagnostic criteria for cognitive impairment and dementia 
Dementia is a syndrome primarily defined by cognitive impairment so severe that it 
interferes with the ability to function in everyday work and social activities. A 
decline from the previous level of functioning also needs to be evident, and the 
decline should not be explained by delirium or a major psychiatric disorder 
(McKhann et al., 2011). According to the fourth edition of American Psychiatric 
Association’s Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
criteria (American Psychiatric Association, 1994) and the International Classification 
of Diseases, 10th revision (ICD-10) (World Health Organization, 1993) criteria, the 
essential cognitive feature of dementia is memory impairment. However, not all 
dementia syndromes have memory impairment as their central symptom; i.e. 
executive functioning, visuospatial abilities, language skills or personality can also 
be affected. 
    In the fifth edition of DSM (DSM-5) published in May 2013, the concept of 
dementia has been replaced with the term major neurocognitive disorder, and memory 
impairment no longer needs to be the central symptom (American Psychiatric 
Association, 2013). In addition, the focus is no longer on the most severe stage of 
impairment. Mild neurocognitive disorder is the diagnosis used for earlier stages of 
cognitive disorders. The newer criteria from the National Institute on Aging and the 
Alzheimer’s Association (NIA-AA) workgroup (McKhann et al., 2011) also 
emphasize the importance of broadening the previous focus on memory 
impairment. 
2.1.2 Diagnostic criteria for Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common cause of dementia. Impairment in 
episodic memory is a characteristic feature of AD, but there are also less common 
nonamnestic forms of AD, particularly visuospatial and logopenic aphasic variants. 
The NIA-AA work group has revised the previous 1984 AD criteria established by 
the National Institute of Neurological and Communicative Disorders and Stroke and 
the Alzheimer’s disease and Related Disorders Association (NINCDS-ADRDA) 
(McKhann et al., 2011). Brain imaging has traditionally been performed to exclude 
other conditions that can cause cognitive impairment, but the new criteria 
emphasize the inclusive role of biomarkers (brain imaging, laboratory exams) in AD 
diagnosis. This is also the case in the research criteria proposed by the International 
Working Group (IWG) in 2007 and 2010 (Dubois et al., 2007; Dubois et al., 2010). The 
IWG criteria refer to medial temporal lobe atrophy (MTA) on magnetic resonance 
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imaging [MRI], cerebrospinal fluid [CSF] markers or positron emission tomography 
[PET]) markers for AD diagnosis (Dubois et al., 2007). 
    The transition from normal cognition to AD dementia is a slow process and many 
elderly individuals can be placed in between these two categories. Mild cognitive 
impairment (MCI) refers to cognitive impairment which is not normal for age, but 
does not meet criteria for dementia and does not significantly affect activities of 
daily living (Winblad et al., 2004). Evidence of a cognitive decline includes self 
and/or informant report and impairment/decline as assessed in objective cognitive 
tasks. The prevalence of MCI varies between 10% and 20% after the age of 65 years 
(Lopez et al., 2003, Petersen et al., 2010, Roberts et al., 2008), and 5-10% of the 
individuals with MCI progress to AD each year (Manly et al., 2008). However, the 
majority of people with MCI in the general population do not develop dementia, and 
a relatively large proportion (20-30%) have been reported to revert to normal 
cognitive status (Ganguli et al., 2011, Manly et al., 2008). Numerous studies have 
investigated the use of biomarkers (alone and in combinations) in predicting 
conversion from MCI to AD, but it is not entirely clear how well such markers 
actually perform outside of specific research settings. However, neuroimaging and 
some other markers have been included as diagnostic tools in the new proposed 
criteria for MCI due to AD (Albert et al., 2011). 
2.1.3 Diagnostic criteria for vascular cognitive disorders 
Vascular dementia (VaD) is the second most common type of dementia (Lobo et al., 
2000). There are several different diagnostic criteria sets for VaD, with the four most 
commonly used being DSM-IV (American Psychiatric Association, 1994), ICD-10 
(World Health Organization, 1993), the State of California Alzheimer’s Disease 
Diagnostic and Treatment Center's (ADDTC) criteria (Chui et al., 1992) and the 
National Institute of Neurological Disorders and Stroke-Association Internationale 
pour la Recherche et l’Enseignement en Neurosciences (NINDS-AIREN) criteria 
(Roman et al., 1993). The NINDS-AIREN criteria are generally used in clinical trials 
and the following features are required for VaD: cognitive decline from previous 
level, impairment of memory and deficits at least in two other cognitive domains, 
focal neurological signs or symptoms, vascular-related changes in brain imaging, 
and an abrupt or fluctuating disease course. VaD is a very heterogeneous condition 
including both cortical lesions (multi-infarct dementia) and subcortical lesions 
(subcortical ischemic vascular disease, strategic infarct dementia). This means that 
there are variations in cognitive profile and disease patterns between patients, 
making it difficult to formulate comprehensive and comparable diagnostic criteria 
(Verhey et al., 1996). Furthermore, the VaD criteria have been suggested to be 
“Alzheimerized” because memory impairment occupies such a central position in 
almost all VaD criteria, although many patients have deficits in other cognitive 
domains (O'Brien et al., 2003). Vascular cognitive impairment (VCI) refers to all 
levels of cognitive impairment caused by cerebrovascular disease (CVD) (O'Brien et 
al., 2003). CVD is an umbrella term for different vascular pathologies affecting the 
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brain, such as stroke, small vessel disease (SVD) including white matter (WM) 
changes (syn. WM hyperintensities, WM lesions, leukoaraiosis), lacunar infarcts, 
microinfarcts and microbleeds. A new set of criteria has been recently proposed for 
vascular cognitive disorders in the International Society for Vascular Behavioral and 
Cognitive Disorders (VASCOG) statement (Sachdev et al., 2014), in an attempt to 
provide a coherent approach to this diverse group of disorders. These criteria are in 
line with the DSM-5 criteria, and take into account the developments in other 
cognitive disorders (e.g. AD). 
2.1.4 Diagnostic criteria for cognitive impairment with multiple causality 
Older individuals with cognitive impairment often have a combination of 
pathologies in the brain, making it difficult to determine with certainty the 
contribution of each pathology to the clinical syndrome. In particular, the overlap 
between AD and CVD has attracted more attention. The previous concept of mixed 
dementia is currently considered as too ambiguous and is no longer recommended. 
The VASCOG statement recommends that clinicians should first make a syndromal 
diagnosis of mild or major neurocognitive disorder, and then decide which 
pathology is more predominant (Sachdev et al., 2014). The proposed diagnoses are 
e.g. mild/major vascular cognitive disorder with AD, or AD with vascular cognitive 
disorder (with the level of certainty of primary cause as ‘possible’ and not 
‘probable’) (Sachdev et al. 2014). DSM-5 refers to the diagnoses of major or mild 
neurocognitive disorder as being due to multiple etiologies (American Psychiatric 
Association, 2013). 
2.1.5 Etiology of Alzheimer’s disease 
The etiology of AD is still not fully clear. Over 20 years ago the amyloid hypothesis 
was formulated (Hardy and Allsop, 1991), and since then it has been the strongest 
candidate to explain the pathogenesis of AD. The amyloid hypothesis in its earliest 
form suggested that amyloid beta protein (A) accumulated into brain parenchyma 
as insoluble neuritic plaques (NP) which started a neurotoxic cascade (Hardy and 
Allsop, 1991). This version of the amyloid hypothesis has been revised and it is 
currently thought that it is the soluble oligomers of A that are actually neurotoxic 
(Hardy and Selkoe, 2002). A oligomers are believed to disrupt neuronal synapse 
function, leading to neuronal damage and to the appearance of intracellular 
aggregations of hyperphosphorylated tau protein (neurofibrillary tangles, NFT). The 
elevated intracellular NFT formation leads to widespread neuronal damage and 
brain atrophy, and ultimately to clinical dementia (Hardy and Selkoe, 2002). 
Although the amyloid hypothesis is widely supported, it has raised many questions 
and criticisms (Drachman, 2014, de la Torre, 2004, Hardy and Selkoe, 2002). High 
intracerebral concentrations of A have been shown to decrease memory and 
synaptic plasticity in rodents (Puzzo and Arancio, 2013), but interestingly picomolar 
concentrations have been reported to have beneficial effects (Puzzo et al., 2008). In 
fact, the physiological functions of A are still poorly understood with some of the 
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partly unresolved questions being: Are amyloid and its oligomers as neurotoxic for 
human neurons as previously thought? Why can some elderly people have a notable 
amount of neuritic plaques at autopsy, but have displayed no cognitive impairment? 
Why have immunotherapies focusing on clearance of insoluble A failed to improve 
cognition? It is possible that the amyloid hypothesis alone may not be enough, and 
AD should be considered more as a syndrome where multiple factors such as 
vascular pathology or inflammation exert additional influences. 
    Tau pathology is thought to progress in phases and the brain atrophy in AD tends 
to follow the same structural pattern (Braak and Braak, 1995, Whitwell et al., 2008). 
A depositions measured by Pittsburgh compound B positron emission tomography 
(PiB-PET) also showed correlation with brain atrophy (Bourgeat et al., 2010, Dore et 
al., 2013). Interestingly, the rate of brain atrophy in antemortem MRI did not 
correlate with A burden measured by immunohistology in post-mortem autopsy 
samples (Josephs et al., 2008). In familial AD, structural brain changes are 
encountered decade(s) before the appearance of any clinical symptoms (Bateman et 
al., 2012, Fox, 2012, Reiman et al., 2012), but brain atrophy preceding sporadic AD 
probably starts later (Jack et al., 2004, Jack et al., 2010, Jagust et al., 2006). Atrophy as 
well as the preceding tau pathology starts from the medial temporal lobe structures, 
initially affecting the entorhinal cortex, later progressing to other parts of the limbic 
system, and finally involving the neocortex (Liang et al., 2013). This is the case in the 
typical late-onset AD, but in the early-onset AD, medial temporal lobe structures are 
often preserved and atrophy is observed in the parietal lobes instead (Karas et al., 
2007). Other more uncommon disease progression patterns have also been reported 
(Whitwell et al., 2012). In the final stages of AD, brain atrophy is extremely diffuse 
and extending over the whole cerebral cortex and also involving subcortical 
structures. 
2.1.6 Etiology of vascular cognitive disorders 
WM lesions (WML) are a characteristic feature of vascular cognitive impairment 
caused by SVD. WML appear as hyperintensities in cerebral WM on T2-weighted 
MRI, and are generally classified as periventricular or subcortical based on their 
location (Figure 1). WML are a very common finding in the general population. 
About 70-88% of people aged 50-65 years have some degree of WML, and around 
20% of people older than 65 years exhibit severe changes (Launer, 2004). The most 
often seen WML are age-related and are particularly strongly associated with 
hypertension. The loss of smooth muscle cells from the tunica media, narrowing of 
the lumen due to fibro-hyaline deposits (i.e. hyalinosis) and atheromas, and 
thickening of the vessel wall are the main characteristics of this arteriolosclerosis-
type of WML. These changes are thought to impair autoregulation, leading to tissue 
hypoperfusion and finally to ischemia and demyelination (Pantoni, 2010). Increased 
oxygen extraction is also seen in the areas of WML, supporting their ischemic origin 
(Kalaria et al., 2012). In addition, blood-brain barrier damage, local subclinical 
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inflammation, oligodendrocyte apoptosis, and cerebral amyloid angiopathy (CAA) 
have been postulated to have a role in the pathogenesis of WML (Pantoni, 2010). 
 
Figure 1. WML on T2-weighted FLAIR MRI. Red arrows point periventricular WML and 
yellow arrows subcortical WML. 
     
Microbleeds are small hemorrhages inside the brain parenchyma. They can be seen 
at autopsy or in MRI if the appropriate MR sequence (such as gradient-echo) is used. 
CAA is often seen in AD and it predisposes the blood vessels to hemorrhaging. 
Lacunar infarcts are small infarcts usually situated deep in subcortical WM or GM 
nuclei. They are caused by occlusion of perforating arteries and hypertension is 
thought to be the main risk factor (Roman et al., 2002). Symptoms vary depending 
on the location and amount of lacunes. In addition, cortical microinfarcts in vascular 
watershed areas may be seen as a consequence of cerebral hypoperfusion (Suter et 
al., 2002). 
    SVD is associated with a cognitive impairment (Pantoni et al., 2007) and increased 
risk of dementia (Savva et al., 2009). In contrast to AD, a deficit in episodic memory 
is not always present, and impairment in executive functioning can often be seen 
(Gunning-Dixon and Raz, 2000). Mood (O'Brien et al., 1998), gait (Baezner et al., 
2008, Baloh et al., 2003) and urinary (Poggesi et al., 2008) problems are also present 
in SVD. SVD-related problems may be more difficult to diagnose with criteria 
focusing on memory impairment. In addition, the diagnostic criteria for VaD have 
been heterogeneous and designed primarily for detecting large-vessel disease 
(Wiederkehr et al., 2008). The importance of mild SVD in midlife is still unclear, 
because not all lesions are associated with cognitive and functional disabilities. The 
location of WML may also be important, e.g. periventricular WML have been 
suggested to exert a greater negative impact on cognition than subcortical lesions 
(Bolandzadeh et al., 2012). However, clinically silent SVD may signal an increased 
vascular risk profile and the need for better risk factors control. 
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    WML often co-exist with AD-type pathology (Pantoni et al., 2009) and brain 
atrophy (Appelman et al., 2009), which has initiated a debate about the role of WML 
in AD. Vascular lesions can lower the threshold for AD pathology to cause clinical 
symptoms in elderly people (Schneider et al., 2007, Snowdon et al., 1997, Toledo et 
al., 2013). In addition, animal experiments suggest that A deposition in the vessel 
wall can disrupt the normal function of endothelial cells, exposing the brain to 
ischemic injury (Iadecola, 2003). Many people with an AD diagnosis have a mixture 
of both AD- and vascular-type pathologies, and ‘pure’ AD may be less common than 
previously thought (Kivipelto et al., 2009, Neuropathology Group. Medical Research 
Council Cognitive Function and Aging Study, 2001). 
2.1.7 Brief overview of risk factors for cognitive impairment and dementia 
Older age (Ritchie and Kildea, 1995), female sex (Fratiglioni et al., 2000) and family 
history (van Duijn et al., 1991) are established risk factors for AD. The effects of 
genes are more pronounced in forms of AD with onsets before the age of 65 years 
(i.e. early-onset AD). Familial AD is often characterised by mutations in three genes: 
amyloid precursor protein (APP), presenilin 1 (PSEN1) and presenilin 2 (PSEN2) 
(Tanzi and Bertram, 2001). However, these familial forms of AD are very rare, 
affecting only 1-2% of AD cases. Apolipoprotein E (ApoE) has an important role in 
cholesterol metabolism, and the 4 allele of the apolipoprotein E gene (APOE 4) has 
been linked with an elevated risk of sporadic AD. It has been estimated that APOE 
4 accounts for about 60% of the genetic component of sporadic AD (Rubinsztein 
and Easton, 1999). A variety of other genes have been proposed as risk factors for 
AD (www.alzgene.org). 
    It has been suggested that there are several modifiable risk factors for AD, in 
particular there is stronger epidemiological evidence for midlife hypertension, 
hypercholesterolemia, obesity, smoking, diabetes and cardiac diseases (Polidori et 
al., 2012). Other proposed risk factors are physical inactivity, unhealthy diet, high 
alcohol intake, depression and traumatic brain injury (Solomon et al., 2014). In 
contrast, a high level of education, a physically, socially and mentally active lifestyle, 
moderate alcohol consumption, and healthy diet (e.g. Mediterranean diet) have been 
postulated to have protective effects against dementia (Solomon et al., 2014). 
 
2.2 VASCULAR RISK FACTORS AND THE AGING BRAIN 
2.2.1 Blood pressure and dementia 
A low BP at older ages was associated with an increased risk of AD in earlier cross-
sectional studies (Guo et al., 1996, Landin et al., 1993). Subsequently, several large 
longitudinal studies showed that high BP in midlife increased the risk of 
AD/dementia after 20-30 years (Kivipelto et al., 2001b, Launer et al., 2000). It has also 
been reported that BP levels actually decrease when the disease progresses (Burke et 
al., 1994). The decline in BP seems to start at least three years before diagnosis (Qiu 
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et al., 2004), possibly even earlier (Skoog et al., 1996). The decrease in BP begins 
earlier particularly in individuals with cardiovascular disorders (Qiu et al., 2004). 
 
2.2.2 Blood pressure regulation 
The brain is an important part of the complex system regulating BP. The role of 
kidneys and the adrenal glands in BP regulation through the renin-angiotensin 
system (RAS) is well recognized (Herichova and Szantoova, 2013), but specific brain 
regions are also involved in BP regulation. Many brainstem nuclei regulate vascular 
tone through the autonomic nervous system, and the brainstem is itself controlled by 
subcortical structures such as thalamus (Dampney et al., 2003). The hypothalamus 
synthetises anti-diuretic hormone (ADH) which regulates blood osmolality and 
sodium levels, which also have an impact on BP levels (Jennings and Zanstra, 2009). 
    Data from animal and human studies indicate that BP is also regulated by cortical 
modulation. The network consisting of the insular cortex, anterior cingulate gyrus 
and amygdala has an important impact on the central autonomic nervous system 
(Nagai et al., 2010). Insular cortex damage has been associated with BP fluctuations, 
arrhythmia, myocardial injury and baroreceptor sensitivity (Nagai et al., 2010), and 
stimulation of the insular cortex can cause changes in heart rate and BP in humans 
(Oppenheimer et al., 1992). In in vivo studies, the left insular cortex seemed to be 
involved in regulating the parasympathetic tone of the cardiovascular system, while 
the right insular cortex was more extensively involved in regulating sympathetic 
tone (Oppenheimer et al., 1992). This central nervous system network has been 
referred to as the “Brain-Heart Axis” (Nagai et al., 2010). 
2.2.3 The brain as a target organ for hypertension 
Brain tissue is greatly dependent on the vasculature. Systemic arterial BP levels vary 
during the day, but autoregulation of brain arterioles ensures an appropriate 
cerebral blood flow (CBF) (Strandgaard, 1976). Chronic hypertension can contribute 
to arteriosclerosis, with stiffening and thickening of the arteriole walls and 
dysfunctional autoregulation. The affected vessels cannot adequately adjust their 
lumen according to BP level fluctuations, leading to hypoperfusion and tissue 
hypoxia (Feldstein, 2012). It seems that autoregulation is relatively well preserved 
with BP values lower than 160/90 mmHg (Serrador et al., 2005), but hypertension 
higher than 160/90 mmHg has been postulated as being harmful (Immink et al., 
2004). Studies in elderly hypertensive individuals detected decreased values of 
regional CBF in the frontal lobe, cingulate cortex and hippocampus, indicative of 
cerebral hypoperfusion in these areas (Beason-Held et al., 2007, Dai et al., 2008). 
Interestingly, cerebral hypoperfusion has also been linked to incident dementia in a 
large prospective study (Ruitenberg et al., 2005). 
    Results from autopsy studies suggest that long-term hypertension is associated 
with an increased accumulation of Alzheimer pathology. A large study of twins with 
a 40 year follow-up time showed increased neocortical and hippocampal NP 
deposition in subjects with high midlife systolic BP (SBP) (Petrovitch et al., 2000). In 
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the same study, individuals with high midlife diastolic BP (DBP) levels had more 
hippocampal NFT compared to controls. Midlife elevated DBP has also been related 
to decreased plasma A levels 15 years before AD diagnosis (Shah et al., 2012). There 
are several hypotheses concerning the mechanisms by which hypertension may 
affect AD pathology, e.g. tissue hypoxia, microinfarctions, inflammation or oxidative 
stress (Feldstein, 2012). In addition, AD pathology can affect the cerebral 
vasculature. A deposition in brain artery walls causes CAA, leading to vessel wall 
rupture, hemorrhages and infarctions (Thal et al., 2008). Furthermore, capillary CAA 
may develop slowly, occluding the vessel lumen, impairing blood flow and causing 
hypoperfusion in the respective vasculature areas (Thal et al., 2008). A is also 
believed to attenuate endothelium-mediated dilatation as a response to 
somatosensory activation, predisposing the brain tissue to hypoperfusion (Niwa et 
al., 2000). 
    The mechanisms underlying the pattern of decline in BP over time observed in 
people who later on develop dementia are not yet clear. One possible explanation 
could be pathological changes/atrophy in brain regions involved in BP regulation. 
Cholinergic neurons stimulate regional blood flow, and atrophy of these neurons 
may disturb normal vessel functioning (Staessen et al., 2007). The NFT burden has 
consistently been related to brain volumes (Gosche et al., 2002, Josephs et al., 2008, 
Nagy et al., 1996, Silbert et al., 2003). NFT pathology reaches the insular cortex 
already in the pre-clinical phase of AD (Braak et al., 1998), and the insula has an 
important role in BP regulation.  
    Midlife hypertension has been related to WML in several epidemiological studies 
(Table 1), and WML have been associated with cerebral atrophy (Appelman et al., 
2009). It is possible that WM changes can affect GM integrity, and vice versa. One 
hypothesis involves Wallerian degeneration (Waller, 1850) in this process. However, 
considering discrepancies between the severity of changes in adjacent cortical and 
WM areas, and the absence of histological markers of Wallerian degeneration in 
affected WM (Pantoni and Garcia, 1997), the relevance of Wallerian degeneration in 
the development of WM changes is still unclear. 
2.2.4 Blood pressure and structural brain changes 
One of the earliest studies investigating the relation between hypertension and brain 
volumes was published in 1984 (Hatazawa et al., 1984). In this cross-sectional study, 
hypertensive subjects had a smaller ratio of brain matter volume to intracranial 
volume, indicative of brain atrophy. Since then many studies focusing on BP and 
brain volumes have been published. Many of these studies have been cross-sectional 
or had short follow-up times, which did not allow any assessment of the long-term 
effects of BP, or of potential reverse causality.  
    Results from cross-sectional studies using different MRI analysis methods indicate 
that the temporal and frontal lobes are particularly vulnerable to the detrimental 
effects of hypertension. Findings vary concerning which structures of medial and 
frontal lobes are affected, but they have been more consistent for a few areas: 
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superior frontal gyrus (Chen et al., 2006, Gianaros et al., 2006, Leritz et al., 2011), 
medial frontal gyrus (Chen et al., 2006, Leritz et al., 2011, Taki et al., 2008), prefrontal 
cortex (Raz et al., 2003, Raz et al., 2007), inferior temporal gyrus (Raz et al., 2007, Taki 
et al., 2008) and superior temporal gyrus (Chen et al., 2006, Leritz et al., 2011). 
Altogether 14 longitudinal studies on BP and brain volumes with follow-up times 
ranging from 2 to 36 years have been published (Table 1). Both elevated midlife SBP 
and DBP have been linked with total brain volume loss in late-life (DeCarli et al., 
1999a, Heijer et al., 2003, Petrovitch et al., 2000, Swan et al., 1998). This association is 
supported by many cross-sectional studies (Goldstein et al., 2002, Hatazawa et al., 
1984, Manolio et al., 1994, Nagai et al., 2008, Salerno et al., 1992, Schmidt et al., 2004, 
Strassburger et al., 1997), but not all (Enzinger et al., 2005, Korf et al., 2007, Skoog et 
al., 1998). The inconsistencies between reports may be explained by differences in 
study populations and methods (e.g. it can take time for hypertension to affect total 
brain volume), or by reverse causality (i.e. already present brain pathology affecting 
BP). 
    Elevated BP has been linked to a reduced hippocampal volume in three 
longitudinal studies using manual tracing (den Heijer et al., 2005b, Korf et al., 2004, 
Raz et al., 2005). In a study with a 25 year follow-up time, individuals with high 
values of midlife SBP and DBP had reduced hippocampal volumes in late-life (Korf 
et al., 2004). Low amygdala volume (den Heijer et al., 2005b) and low orbitofrontal 
cortex volume (Raz et al., 2005) have also been associated with high BP, but other 
areas such as insular cortex have not been investigated in longitudinal studies. 
    The effects of midlife BP on late-life WML have been assessed in two longitudinal 
studies with follow-up times of around 20 years (Table 1). In a study investigating 
twin males, midlife hypertension was related to WML as assessed with MRI 25 years 
later (Carmelli et al., 1999, DeCarli et al., 1999a, Swan et al., 1998). The strengths of 
this study are a large cohort and long follow-up time, but the focus on a twin male 
population makes it difficult to generalize results. The Rotterdam Scan Study, a 
longitudinal population-based study including over 1000 subjects (514 with nearly 
20 years follow-up time), also reported an association between midlife hypertension 
and late-life WML (de Leeuw et al., 1999). In Rotterdam Scan Study, also a J-shape 
relationship was observed between changes in DBP and WML. 
    Longitudinal studies with shorter follow-up times (two to five years) have 
reported an association between baseline hypertension and WML progression 
(Firbank et al., 2007, Raz et al., 2007, Schmidt et al., 1999, Verhaaren et al., 2013). 
Interestingly, a diffusion tensor imaging (DTI) study showed WM injury in 
hypertensive (SBP   	
    ) individuals younger than 40 years 
(Maillard et al., 2012). It is difficult to draw clear conclusions concerning the 
importance of SBP versus DBP, because findings from various studies are 
inconsistent (Table 1). Variations between different studies can also be seen 
concerning the relationships of SBP or DBP with brain GM volumes (Table 1) 
(Beauchet et al., 2013). 
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2.2.5 Adiposity and dementia 
Midlife adiposity (i.e. overweight, obesity) has been associated with an increased 
risk of dementia in longitudinal population-based studies (Kivipelto et al., 2005, 
Whitmer et al., 2005a). As with BP, the association seems to depend on age and a 
lower BMI was linked to dementia at older ages (Atti et al., 2008, Nourhashemi et al., 
2003). Loss of weight a few years before AD diagnosis is thought to be a marker of 
incipient dementia rather than a risk factor for AD (Gustafson, 2012). 
    Several mechanisms may explain the association between adiposity and AD, e.g. 
vascular factors, hyperinsulinemia, advanced glycocylation products, adipokines, 
cytokines and leptins produced by adipose tissue (Luchsinger and Gustafson, 2009). 
Adipose tissue is hormonally very active, and inflammation-related adipokines as 
well as dietary regulation-related leptins have been associated with AD and brain 
GM volumes (Gustafson, 2012, Rajagopalan et al., 2013). However, these 
mechanisms are still not entirely clear (Luchsinger and Gustafson, 2009). 
2.2.6 Adiposity and structural brain changes 
Low BMI at older ages and a declining BMI over time have been associated with AD 
neuropathology (A and NFT) at brain autopsy as well as with CSF markers and 
PiB-PET-imaging (Buchman et al., 2006, Vidoni et al., 2011). This is in line with 
findings from epidemiological studies concerning late-life BMI and AD risk. In 
addition, elevated BMI during 24 years follow-up in elderly people was associated 
with lower temporal lobe volume as measured with computerized tomography (CT) 
in late-life (Gustafson et al., 2004a). Increased BMI values were related to lower total 
GM volume in otherwise healthy middle-aged postmenopausal women (Soreca et 
al., 2009). Similar results have been reported in studies with shorter follow-up times 
(Bobb et al., 2012, Driscoll et al., 2012, Enzinger et al., 2005). Increased BMI has also 
been associated with cortical thinning in a cognitively healthy middle-aged 
Norwegian population after an average follow-up of 3.6 years (Walhovd et al., 2013). 
    The extent WML have been linked with adiposity in one longitudinal Swedish 
study (Gustafson et al., 2004b). In a sample of 70 years old women followed-up for 
18 years, CT scans were performed at the age of 85-88 years. Every 1.0 increase in 
BMI at the age of 70 doubled the risk of WML later on. Several cross-sectional 
studies investigating WM integrity as assessed with either DTI or proton magnetic 
resonance spectroscopy (1H MRS) support this finding (Gazdzinski et al., 2008, 
Mueller et al., 2011, Stanek et al., 2011, Verstynen et al., 2012). A recent Japanese 
cross-sectional study investigating 35-74 years old (mean 55.3 years) office workers 
without any prior cerebrovascular disease linked increased visceral fat accumulation 
with WML and lacunar infarcts. Interestingly, no association was found between 
high BMI and WML or lacunes, suggesting that it was visceral fat accumulation 
rather than general obesity and subcutaneous fat accumulation which seemed to be 
more harmful for cerebral white matter (Yamashiro et al., 2014). 
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2.2.7 Cholesterol and dementia 
Elevated total cholesterol in midlife has been linked to increased risk of 
AD/dementia in longitudinal studies (Kivipelto et al., 2001b, Whitmer et al., 2005b). 
Studies with shorter follow-up times and older populations have reported 
conflicting results. Similarly to BP and BMI, total cholesterol levels seem to decline 
over time in individuals who susequently develop dementia (Solomon et al., 2007).  
    Midlife total cholesterol levels have been related to accumulation of A and NFT 
in autopsy studies (Launer et al., 2001). In addition, animal studies have revealed 
accumulation of A and NFT in animals with cholesterol-rich diet (Rahman et al., 
2005, Sparks et al., 1994). In middle-aged people, higher total cholesterol levels were 
associated with glucose hypometabolism in brain regions relevant for AD (Reiman et 
al., 2010). Cholesterol has an important role in atherosclerosis, and vascular 
pathology may partly explain the association with AD/dementia. Other mechanisms 
may involve oxysterols, cholesterol metabolites which can pass through the blood-
brain barrier and function as a link between the circulating and brain cholesterol 
pools (Björkhem et al., 2009).  
2.2.8 Cholesterol and structural brain changes 
Results on the association of cholesterol with structural brain changes are 
inconsistent. Low high density lipoprotein (HDL) was associated with reduced 
hippocampal volume (Wolf et al., 2004), but a larger study including subjects 
without dementia did not confirm this finding (den Heijer et al., 2005a). A large 
cross-sectional Swedish study revealed that men with hypercholesterolemia had 
smaller volumes of hippocampal and entorhinal cortex as compared to controls (Qiu 
et al., 2012), but this association was not detected in other studies (Koschack et al., 
2009, Wolf et al., 2004). Surprisingly, increasing cholesterol levels were linked with 
thicker cortex across the whole brain in one cross-sectional study including subjects 
with no history of cerebrovascular or neurological diseases (Leritz et al., 2011). Low 
midlife HDL levels were associated with higher WML load at late-life, but no 
association was seen for low density lipoprotein (LDL) or total cholesterol and WML 
(Carmelli et al., 1999). The role of cholesterol in dementia-related diseases is difficult 
to evaluate because peripheral and brain cholesterol metabolism are separated by 
the blood-brain barrier, and the links between the two cholesterol pools are not 
entirely clarified (Björkhem et al., 2009). 
2.3 HEART DISEASES AND THE AGING BRAIN 
2.3.1 Heart diseases and dementia 
Coronary heart disease (CHD) has been associated with dementia in several 
longitudinal studies (Aronson et al., 1990, Brayne et al., 1998, Ross et al., 1999), but 
findings with regard to AD specifically are less consistent (Brayne et al., 1998, 
Hayden et al., 2006). Autopsy studies have shown increased accumulation of AD 
neuropathology in individuals with CHD and without dementia (Sparks et al., 1990), 
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and this association was even stronger in APOE 4 carriers (Beeri et al., 2006). 
Having CHD in midlife increased the risk of poorer cognitive functioning in a study 
with an 11 year follow-up time (Singh-Manoux et al., 2003), but this finding was not 
supported by other epidemiological studies (Bursi et al., 2006, Grubb et al., 2000). 
Similar to the situation with CHD, heart failure (HF) (Qiu et al., 2006) and atrial 
fibrillation (AF) (Bunch et al., 2010, Miyasaka et al., 2007) have also been linked with 
cognitive impairment, although with inconsistent findings (Marengoni et al., 2011, 
Peters et al., 2009). AF is a major risk factor for stroke, but an independent 
association between AF and AD/dementia has also been reported (Bunch et al., 2010, 
Miyasaka et al., 2007, Ott et al., 1997).  
2.3.2 Coronary heart disease and structural brain changes 
Several cross-sectional studies have focused on CHD and brain GM or WM changes 
(Table 2), but so far no longitudinal studies have taken disease duration into 
account. CHD was associated with decreased brain volume in a population of twin 
veterans in USA, with the association being more pronounced among APOE 4 
carriers (DeCarli et al., 1999b). A Dutch study reported decreased hippocampal 
volume in subjects with CHD in a small sample of middle-aged participants, but no 
differences were found in total brain volume (Koschack and Irle, 2005). Interestingly, 
regions associated with AD such as temporal lobe, posterior cingulate and 
precuneus had lower volumes in individuals with prior myocardial infarction in a 
small study including 18 non-demented subjects (Almeida et al., 2008). CHD was not 
related to structural brain changes (visual rating of ventricular enlargement, sulcal 
widening and WML) in the Cardiovascular Health Study (Manolio et al., 1994). 
Measures of atherosclerosis such as coronary artery calcification (CAC) and internal 
carotid artery calcification, were associated with WML in several studies, and this 
association was independent of several vascular risk factors (Table 2). The larger 
AGES-Reykjavik study also reported associations between CAC and brain GM and 
WM volumes (Vidal et al., 2010). Furthermore, a study using 1H MRS detected 
impaired WM integrity already in midlife in people with subclinical atherosclerosis 
(Haley et al., 2010). 
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HF and AF can be related to CHD, but they can also occur and affect the brain 
independently of CHD (Roman, 2004, Stefansdottir et al., 2013). Previous studies of 
HF and brain morphology have had smaller sample sizes as compared to the CHD 
studies, but more innovative MRI methods have been used and the results seem to 
be more consistent. Three studies utilized an automatic whole brain segmentation 
method to evaluate possible relations between different brain regions and HF 
(Almeida et al., 2012, Woo et al., 2003, Woo et al., 2009). All three studies showed 
lower regional brain volumes throughout the whole cerebrum in people with HF 
compared to controls. Temporal lobe, cingulate and insular cortex were particularly 
affected. Visually rated MTA was more pronounced in patients with HF (Beer et al., 
2009, Vogels et al., 2007), and a general GM volume loss was also seen (Bhattacharya 
et al., 2012, Schmidt et al., 1991). Only one study detected an association between HF 
and WML (Vogels et al., 2007). In this study, the relationships of HF with MTA and 
WML were clearer as compared to CHD. Similar results were found in another study 
(Almeida et al., 2012), suggesting that the effects of HF on brain changes were at 
least partly independent of CHD. A small DTI study investigating middle-aged 
people showed decreased axonal integrity in autonomic, cognitive and emotional 
regulatory areas in HF patients as compared to controls (Kumar et al., 2011). 
    Six studies have so far focused on AF and structural brain changes. One study had 
a five year follow-up time (de Leeuw et al., 2000), another gathered information 
about disease duration (Stefansdottir et al., 2013), while the rest were cross-sectional 
(Knecht et al., 2008, Kobayashi et al., 2012, Manolio et al., 1994, Seshadri et al., 2004). 
A large Icelandic cohort study detected a significant association of AF with lower 
total and GM volumes and more WML (Stefansdottir et al., 2013). The association 
with total brain and GM volumes was stronger for persistent AF and for longer 
disease duration, which may explain the earlier negative results (Knecht et al., 2008, 
Manolio et al., 1994, Seshadri et al., 2004). The manually traced hippocampal volume 
in a sample of subjects without dementia was lower in individuals with AF 
compared to controls (Knecht et al., 2008). AF was associated with WML in two 
other populations (de Leeuw et al., 2000, Kobayashi et al., 2012). 
2.3.3 Heart diseases and dementia - possible mechanisms of association 
The effects of heart diseases on the brain may be partly related to vascular risk 
factors such as hypertension or hypercholesterolemia. However, findings from 
several studies focusing on structural brain changes and heart diseases remained 
significant even after adjustments for vascular risk factors, and thus other 
mechanisms may also exist. In patients with HF, left ventricular dysfunction 
together with impaired brain arterial autoregulation may lead to cerebral 
hypoperfusion, especially in watershed areas such as periventricular WM, 
hippocampus and insula (Roman, 2004). Hypercoagulopathy occurs in AF due to 
impaired blood flow in the atriums of the heart, predisposing patients to embolic 
strokes. Apart from major strokes affecting the large arteries, microembolisms may 
also occlude small arterioles causing microinfarcts and subsequent atrophy 
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(Stefansdottir et al., 2013). Furthermore, both CHD and AF may cause left ventricular 
dysfunction leading to cerebral hypoperfusion. CHD may additionally reflect 
systemic atherosclerosis affecting small cerebral arteries/arterioles, with vessel 
occlusion and microinfarcts. 
2.4. RISK ESTIMATION TOOLS FOR PREDICTING DEMENTIA  
At present, two dementia risk scores based on demographic, lifestyle and vascular 
risk factors have been developed (Kivipelto et al., 2006, Mitnitski et al., 2006). The 
CAIDE Dementia Risk Score estimates the risk of dementia occuring 20 to 40 years 
later based on the midlife risk profile (Exalto et al., 2013, Kivipelto et al., 2006); it 
achieved moderate prediction accuracy both in the original and in a validation study 
(area under curve [AUC] 0.77 and 0.75, respectively). The CAIDE Dementia Risk 
Score consists of easily measurable factors (age, sex, education, SBP, BMI, total 
cholesterol, physical activity), which makes it easy to use in general practice settings. 
Another risk index included 23 different vascular risk factors (+sex) and was 
developed to predict the risk of dementia and death after 10 and 20 years (Mitnitski 
et al., 2006). The accuracy of distinction between individuals without dementia and 
those with dementia was moderate after 10 years (AUC 0.74), and decreased when 
the follow-up time was prolonged to 20 years (AUC 0.67).  
    A more complex dementia risk index was developed to predict shorter-term 
dementia risk in older individuals (Barnes et al., 2009). This risk index showed 
slightly better separation accuracy (AUC 0.81) than the CAIDE Dementia Risk Score, 
but it also contains more laborious variables such as cognitive and physical tests, 
neuroimaging parameters and internal carotid artery wall thickness. A simplified 
version of the risk index has also been published (Brief Dementia Risk Index [BDRI]), 
providing almost as good separation accuracy (AUC 0.77) between individuals with 
and without dementia as the original risk index (Barnes et al., 2010).  
    In another study, aggregation of factors related to atherosclerosis (high SBP, 
diabetes/prediabetes, stroke) or brain hypoperfusion (low DBP and pulse pressure 
[PP], HF) was shown to approximately double the dementia risk in elderly people 
after nine years of follow-up (Qiu et al., 2010). Interestingly, the Framingham general 
cardiovascular disease risk score (D'Agostino RB et al., 2008) and Framingham 
stroke risk score (D'Agostino et al., 1994) showed slightly stronger associations with 
the cognitive decline in multiple domains as compared to the CAIDE Dementia Risk 
Score in a large British longitudinal study (Kaffashian et al., 2013). Dementia 
diagnoses were not available in that study, which may partly explain the results. 
There were also notable differences between risk score variables. For example, both 
Framingham risk scores included diabetes (which is not included in CAIDE 
Dementia Risk Score), and diabetes showed the strongest independent association 
with cognition of all the variables evaluated in that study. However, in a large 
Northern American cohort, dementia predictability was not improved when 
diabetes or several other risk factors were added to the CAIDE Dementia Risk Score 
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(Exalto et al., 2013). The risk scores based on demographic, physical and vascular 
risk factors seem to predict dementia well, but it is still unknown whether they relate 
to vascular more than to neurodegenerative pathologies. The Framingham 
cardiovascular risk profile was inversely associated with GM volume and thickness 
in a cross-sectional study (Cardenas et al., 2012), but these associations need to be 
investigated in longitudinal studies. 
2.5. STRUCTURAL MRI AND THE AGING BRAIN 
2.5.1 Basic MRI sequences in dementia-related disorders 
T1, T2, and Fluid Attenuated Inversion Recovery (FLAIR) are the basic sequences 
most often used for dementia-related disorders. In addition, diffusion weighted 
imaging (DWI) has been used for younger patients or in rapidly progressive disease 
forms, and T2* is especially good for detecting microbleeds. T1-weighted MRI may 
be considered as an “anatomy scan” due to its good ability to separate fluid from fat, 
providing an appreciable contrast between GM and WM (Figure 2). T1-weighted 
MRI can also be acquired rapidly due to its short repetition time (TR). T2-weighted 
MRI is called the “pathology scan” because of its ability to identify edema (e.g. 
around tumors) and small infarcts. T2-weighted images take longer to acquire due to 
the prolonged TR. FLAIR-weighting is similar to T2, but in FLAIR, the signal from 
fluids is attenuated (fluids are black). This makes easier the separation between CSF 
and WML. 
 
              T1-weighted                        T2-weighted                             FLAIR 
Figure 2. The basic MR sequences used in memory disorder imaging 
2.5.2 MRI and brain structures – visual methods 
Most visual rating scales were initially developed for research use, but due to their 
rapidity and sufficient accuracy, some of them have become established in clinical 
settings. The most widely used visual rating scale for MTA evaluates the width of 
the choroid fissure and temporal horn and volume loss of hippocampus (Figure 3) 
(Scheltens et al., 1992). The Scheltens scale has proved to be good at separating 
healthy controls from patients with AD, with specificity and sensitivity values of 76-
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90% and 70-90%, respectively (Scheltens et al., 1997, Wahlund et al., 2000). The 
Scheltens scale showed slightly lower accuracy as compared to automatic and 
manual segmentation of hippocampus when distinguishing healthy controls from 
patients with AD. However, the differences were small, especially between visual 
rating and automatic segmentation (81% and 83%, respectively) (Westman et al., 
2011). 
 
Figure 3. Visual rating of MTA on CAIDE participants. No medial temporal lobe atrophy 
was seen in the first coronal T1-image (MTA=0 bilaterally; control subject). In the 
second image, MTA was scored as 2 bilaterally (control). In the last image, MTA was 
scored as 3 on the left side and 2 on the right side (AD). 
MTA is of special interest in the evaluation of memory clinic patients, but 
radiological assessment of vascular changes is also important. Several visual rating 
scales for evaluating WML have been developed (Mantyla et al., 1997, Wahlund et 
al., 2001). There are differences between rating scales and these need to be 
considered when comparing the results from different studies (Mantyla et al., 1997). 
The simplest scales do not differentiate between periventricular WML, subcortical 
WML or regional positioning (Breteler et al., 1994, Herholz et al., 1990, Schmidt et al., 
1992, Wahlund et al., 1990). More complex scales rate WM changes according to their 
size, anatomical position, type and formation (Scheltens et al., 1993). The highly 
reproducible and easily applicable Fazekas scale (Fazekas et al., 1987) is widely used 
in clinical settings and it shows a good correspondence with other more detailed 
scales (Scheltens et al., 1998). Similarly to the Fazekas scale, the Age-Related WM 
Changes (ARWMC) scale (Wahlund et al., 2001) uses a four-point rating system, but 
WML are divided based on their regional position. The ARWMC scale can be used 
with both MRI and CT (Figure 4). The characteristics of some of the WML rating 
scales are shown in Table 3. 
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Figure 4. Example of the ARWMC rating scale on FLAIR MRI. The red arrow points to a 
rating score of 1 for the right parieto-occipital area. The yellow arrow indicates a rating 
score of 2 for the right frontal area. The blue arrow indicates a rating score of 3 for the 
right parieto-occipital area. 
 
Table 3. Characteristics of selected WML rating scales 
Scale PWML/DWML  Lesion size/form Regional position Points 
Fazekas (1987) Distinct Verbal No PWML: 0-3 
DWML: 0-3 
Schmidt (1992) Combined Verbal No WML: 0-3 
Scheltens (1993) Distinct Numerical Yes PWML: 0-6 
DWML: 0-24 
BGWML: 0-30 
ITWML: 0-24 
ARWMC (2001) Combined Verbal Yes WML: 0-24* 
BGWML: 0-6* 
 
PWML=periventricular WML; DWML=deep WML; ITWML=infratentorial WML; BGWML=basal 
ganglia WML 
*Left and right hemispheres are rated separately. 
 
2.5.3 MRI and brain structures – manual and automatic methods 
Visual rating scales provide qualitative and, at best, semi-quantitative data, but GM 
structures and WML can also be delineated by hand in order to obtain quantitative 
volumes. For example, at least 71 different manual delineating protocols for 
hippocampus have been published (Konrad et al., 2009). In principle, any brain 
structure or pathology with clear boundaries can be manually segmented (Goldstein 
et al., 2005, Looi et al., 2008, Raz et al., 1997). Manual delineation of hippocampus is 
considered to be the golden standard when studying hippocampal volume, and 
findings from a recent study of the accuracy in predicting AD based on hippocampal 
manual, automated and visual analysis confirm this view (Westman et al., 2011). 
Although it has a better segmentation accuracy, manual segmentation is a laborious 
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and time consuming process. All visual rating and manual delineation methods are 
also operator-sensitive, leaving space for human error. 
    Automatic whole-brain analysis methods have become more common in past 
decade. These methods enable the inspection of multiple brain structures without a 
prior hypothesis. Several automatic cerebral cortex thickness measuring pipelines 
are available (Fischl and Dale, 2000, Jones et al., 2000, Lerch and Evans, 2005, 
MacDonald et al., 2000), and one of the most widely used is FreeSurfer, a freeware 
software published by Fischl and Dale in 2000. FreeSurfer is actually a set of 
software tools, because in addition to cortical thickness measurements, it can also 
provide cortical and subcortical volumes. The procedure published by Lerch and 
Evans (Montreal method) is similar to FreeSurfer, with some methodological 
differences (http://www.bic.mni.mcgill.ca/). For example, the pipelines use different 
distance metrics which may produce variations in results, but the differences are 
probably not so pronounced (Lerch and Evans, 2005). An overview of the steps 
involved in the Montreal method is presented in Figure 5. 
     
 
 
Figure 5. Overview of the Montreal method steps for cortical thickness analysis. First, 
images are non-uniformity corrected and registered into stereotaxic space. They are 
then classified (1) and fitted with a WM surface (2). The GM surface is found by 
expanding out from the WM surface (3). Cortical thickness is measured at every vertex 
(4), and blurred using a 20 mm surface-based kernel (5). Reprinted from Lerch et al. 
(2005) with permission from Oxford University Press. 
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Similarly to the situation with GM structures, WML manual delineation is laborious 
and time consuming. For this reason, there is a great need for automatic analysing 
procedures.  Most automatic WML analysing methods use training data sets and 
machine learning algorithms for classifying voxels as WML or normal intracranial 
tissue/fluid (Anbeek et al., 2004, Damangir et al., 2012, Johnston et al., 1996, Khayati 
et al., 2008, Lao et al., 2008). Methods relying purely on voxel intensities also exist, 
but they tend to produce a high number of false positives (Kloppel et al., 2011). With 
respect to the machine learning algorithms, methods using support vector machine 
(SVM) seem to perform best and the results are even more accurate when 
information is included about neighboring voxels and anatomy (Kloppel et al., 2011).  
     Automatic brain segmentation methods have advanced significantly during the 
past 10-15 years, and the progress will continue in parallel with evolving MR 
cameras and computer power. Fully-automatic methods are fast, operator-
independent (except for the planning, coding and quality check phases), less labor 
compared to manual methods, and are becoming increasingly robust. In general, 
visual rating methods are still mainly used in the clinic, but this can be predicted to 
change in the future. For example, automatic hippocampal segmentation can be 
done in about two minutes using a basic laptop computer (Lotjonen et al., 2011). 
Automatic segmentation of small structures such as the entorhinal cortex is more 
difficult, mainly because of the insufficient resolution of basic MR cameras. In 
addition, tissue intensity variation in GM nuclei (Fischl, 2012), relatively hazy 
borders of WML (Kloppel et al., 2011) and advanced atrophy (Chupin et al., 2009) 
are still challenging for automatic segmentation methods. For these reasons, the 
quality check of segmentation results by a human operator is still an important 
component of structural brain imaging research. 
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3 Aims of the Study 
 
The general aim of the thesis was to investigate long-term associations between 
vascular risk factors and conditions from midlife to late-life and dementia-related 
structural brain changes on MRI in late-life. The specific aims were: 
 
1) To study the associations of midlife blood pressure, BMI and total cholesterol 
with WML two decades later; to investigate changes in blood pressure, BMI 
and cholesterol during 20 years after midlife in relation to WML, as well as 
the effects of APOE genotype (Study I). 
 
2) To study the relationships between midlife blood pressure, BMI, total 
cholesterol, their changes over time and regional cortical thickness measured 
up to 30 years later (Study II). 
 
3) To investigate the long-term effects of CHD on cortical thickness, GM volume, 
and WML volume, taking into account the possible modifying effect of blood 
pressure (Study III). 
 
4) To evaluate the associations between the CAIDE Dementia Risk Score in 
midlife and cortical thickness, GM volume, MTA, and WML up to 30 years 
later (Study IV). 
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4 Subjects and Methods 
 
4.1 CAIDE STUDY AND MRI POPULATIONS 
All four studies in the thesis were based on the Cardiovascular Risk Factors, Aging 
and Dementia (CAIDE) study carried out in Eastern Finland. CAIDE is a 
longitudinal, population-based study focusing on associations of cardiovascular and 
lifestyle-related risk factors with dementia and cognitive functioning. CAIDE 
participants were first evaluated at midlife in 1972, 1977, 1982 or 1987 within the 
North Karelia Project and the Finnish part of Monitoring Trends and Determinants 
in Cardiovascular Disease (FINMONICA) study (Puska et al., 1979, Puska et al., 
1983, Vartiainen et al., 1994). These studies were conducted to evaluate the risk 
factors, morbidity and mortality related to cardiovascular diseases. In 1972 and 1977, 
a random sample of 6.6% of the population born in 1913-1947 and living in Kuopio 
and North Karelia provinces was drawn. In 1982 and 1987, the stratified sample of 
persons aged 25-64 years and living in Kuopio or North Karelia provinces (250 
subjects of each sex and 10-year age group from both provinces) was chosen based 
on the international WHO MONICA project protocol (WHO MONICA Project 
Principal Investigators, 1988). 
    The CAIDE study and formation of the MRI populations are presented in Figure 6. 
A random sample of 2000 participants in the North Karelia Project or FINMONICA 
study, aged 65-79 years at the end of 1997, and living in or close to the towns of 
Kuopio and Joensuu were invited to participate at the first re-examination in 1998 
(Kivipelto et al., 2001a). Altogether 1449 (72.5%) individuals participated (Kivipelto 
et al., 2001b) and 61 subjects were diagnosed with dementia (AD, n=48) and 82 
subjects with MCI. A second re-examination was conducted in 2005-2008. All 1426 
persons of the original 2000 who were still alive and living in the geographical area 
of Kuopio or Joensuu were invited, and 909 (63.7%) participated. 68 subjects were 
diagnosed with dementia (AD, n=57) and 171 with MCI. Cognitive status was 
assessed at both re-examinations with a three-step protocol: screening phase, clinical 
phase, and differential diagnostic phase (including brain MRI). The CAIDE MRI 
population at the first re-examination (n=112 participants) included all dementia 
cases from the Kuopio region (n=39), sex- and age- ( 3 years) matched subjects with 
MCI (n=31), and at least one similarly matched cognitively normal control (n=42) for 
each dementia case. The CAIDE MRI population at the second re-examination 
(n=113) included all subjects from the Kuopio cohort attending the differential 
diagnostic phase: 37 with dementia, 70 with MCI, and 6 defined as controls. Only 18 
participants were included in both CAIDE MRI populations. 
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    The CAIDE study was approved by the local ethics committee of Kuopio 
University Hospital and written informed consent was obtained from all 
participants. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. CAIDE study and formation of the MRI populations. 
 
4.2 MRI METHODS 
4.2.1 First CAIDE re-examination (1998) 
Participants in the differential diagnostic phase of the first re-examination were 
scanned using a 1.5 T MR unit (Magnetom Vision Format; Siemens) at Kuopio 
University Hospital. MRI protocol included T1, T2, proton density (PD) and FLAIR 
sequences. All images were visually checked by an experienced neuroradiologist to 
confirm that they were free of artifacts and clinically significant brain conditions 
such as tumors, major post-stroke lesions or normal pressure hydrocephalus. 
    Axial FLAIR images (repetition time [TR]=9000 ms, echo time [TE]=119 ms, flip 
angle=180°, field of view [FOV]=24 cm, Matrix=256x256, slice thickness=5 mm, in 
plane voxel dimension=0.94x0.94) were used to assess WML with a semi-quantitative 
visual rating scale (Wahlund et al., 2001) by a single trained rater blinded to the 
possible diagnoses and other clinical data. The lesions were rated separately for five 
brain regions (frontal, parieto-occipital, temporal, infratentorial and basal ganglia) in 
both hemispheres. Except for the basal ganglia, the rating was done using a 4-
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stepped scale: 0=no changes, 1=focal lesions, 2=incipient confluence of lesions and 
3=diffuse involvement of the entire region, with or without involvement of U fibres. 
Changes in basal ganglia were similarly rated: 0=no changes, 1=focal lesion (
2=more than one focal lesion and 3=confluent lesions. The total WML burden was 
calculated by summing the ratings from all of the separate brain regions from both 
hemispheres. Re-rating of a sub-sample of the images resulted in intra-rater 
correlation coefficient of r=0.98. In addition, the reliability of the WML rating was 
confirmed by an external rater also blinded to the diagnoses and any of the clinical 
data at the time of rating. Comparison of these two ratings led to an inter-rater 
correlation coefficient value of r=0.90. 
    T1-weighted images were assesed using three dimensional magnetization 
prepared rapid acquisition gradient echo (3D-MPRAGE) sequence (TR=9.7ms, 
TE=4ms, flip angle=12°, FOV=25cm, matrix 256x256, slice thickness=2mm, in plane 
voxel dimension=0.98x0.98mm). A single trained rater assessed MTA from T1-
weighted images according to a visual rating scale commonly used in clinical 
practice (Scheltens et al., 1992). MRIs were oriented perpendicular to the anterior 
commisure - posterior commisure line and MTA was rated from a single coronal 
slice at the level where hippocampus, cerebral peduncles and pons were all visible. 
MTA was graded from zero (no atrophy) to four (end-stage atrophy) bilaterally.  
    GM volumes were measured using FAST FSL (FMRIB’s Automated Segmentation 
Tool) (Zhang et al., 2001). FAST segments a 3D MRI of the brain into different tissue 
types (GM, WM, CSF), whilst also correcting for spatial intensity variations (also 
known as bias field or radio frequency inhomogeneities). The underlying method is 
based on a hidden Markov random field model and an associated Expectation-
Maximization algorithm. The whole process is fully automated and can also produce 
a bias field-corrected input image and probabilistic and/or partial volume tissue 
segmentation. 
4.2.2 Second CAIDE re-examination (2005-2008) 
Participants in the differential diagnostic phase of the second re-examination were 
scanned using two different 1.5 T MR units (Magnetom Vision or Avanto; Siemens) 
at Kuopio University Hospital. The MRI protocol included T1, T2, PD and FLAIR 
sequences, and additionally DWI and T2* sequences. All images were visually 
checked by an experienced neuroradiologist to confirm that they were free of 
artifacts and clinically significant brain conditions such as tumors, major post-stroke 
lesions or normal pressure hydrocephalus. 
    3D-MPRAGE T1-weighted MRIs were used for cortical thickness and GM volume 
measurements. The imaging parameters were: Magnetom Vision (TR=9.7 ms, TE=4.0 
ms, TI=300 ms, FA=12°, slice thickness=1.5-2.0 mm, matrix 256x256, number of 
slices=128 or 148) and Avanto (TR=1900 ms, TE=3.93 ms, TI=1100 ms, FA=15°, slice 
thickness=1.0-1.5 mm, matrix 384/448x512, number of slices=160). Data were 
analysed using algorithms developed at McConnell Brain Imaging Centre, Montreal 
Neurological Institute, McGill University, Montreal, Canada 
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(http://www.bic.mni.mcgill.ca/). Initially, individual native MRIs were registered 
into standardized stereotaxic space using the ICBM 152 template and corrected for 
intensity non-uniformity using the N3 algorithm. The N3 algorithm is a fully 
automated technique which maximizes the entropy of the intensity histogram and 
can be applied to any pulse sequences, field strength or MR scanner. Subsequently, 
the images were segmented into GM, WM and CSF using an artificial neural 
network classifier termed INSECT (Intensity-Normalized Stereotaxic Environment 
for Classification of Tissues) (Zijdenbos, 1998). 3D brain mask was calculated to 
remove extra-cerebral voxels and partial volume effect (PVE) was estimated. 
Surfaces between GM and WM (WM surface=WMS) as well as GM and CSF (GM 
surface=GMS) were defined using Constrained Laplacian-based Automated 
Segmentation with Proximities (CLASP) algorithm (Kim et al., 2005). Each polygon 
mesh surface consisted of 81 920 polygons and 40 962 nodes per hemisphere. 
Cortical thickness was defined as the distance between each vertex on WMS and its 
counterpart/linked vertex on GMS. Thickness calculations were performed in native 
space and thereafter transformed back to standardized space to enable group 
analysis. In the final step, cortical thickness maps were smoothed using 20 mm full 
width at half maximum diffusion kernel to increase the signal-to-noise ratio and to 
have more normally distributed data. Finally, the outcome of the pipeline was 
inspected visually to ascertain the quality of the surface estimation. 
    FLAIR parameters were: TR=9000 ms, TE=119 ms, TI=2200 ms, slice thickness=5 
mm, flip angle=180°, matrix=512x168. WML volumes were calculated from T1- and 
FLAIR-images using an automatic pipeline developed at Karolinska Institute, 
Stockholm, Sweden (www.github.com/Damangir/Cascade) (Damangir et al., 2012). 
Pre-processing steps included affine registration of T1- to FLAIR-images; followed 
by brain extraction (Smith, 2002). Manual quality control was performed to inspect 
the brain extraction quality. Then brain tissues segmentation (Zhang et al., 2001) and 
histogram matching was carried out for both sequences. In the main classification, 
each voxel was classified as WML or normal based on the intensities of neighboring 
voxels on T1- and FLAIR-images. Voxels classified as normal were pruned away 
from cascade while the rest proceeded to the next step. Finally after multiple 
classification steps, only voxels classified as WML were left. Next morphological and 
spatial filtering was done to remove WML detections that were too small or in 
dissimilar spatial locations (e.g. in CSF). Finally all detections passed through 
boundary refining and the final output consisted of volumes and masks of the WML. 
By using this novel cascade method, high sensitivity (90%) and specificity (99.5%) 
was achieved when compared to manual delineation of WML (Damangir et al., 
2012). 
    MTA rating in the second re-examination was performed identically to the first re-
examination. 
 
37 
 
4.3 COGNITIVE ASSESSMENTS 
Cognitive status was assessed in both CAIDE re-examinations with a three-step 
protocol: screening phase, clinical phase, and differential diagnostic phase.  
    In the screening phase, each participant and an informant were initially 
interviewed. A specially trained study nurse then carried out preliminary cognitive 
testing including Mini-Mental State Examination (MMSE) (Folstein et al., 1975), 
immediate word recall test (Heun et al., 1998, Nyberg et al., 1997), category fluency 
test (Borkowski et al., 1967), Purdue Peg Board test (Tiffin, 1968), letter-digit 
substitution test (Wechsler, 1944), Stroop test (Stroop, 1935), prospective memory 
task (Einstein et al., 1997) and subjective memory rating (Bennett-Levy and Powell, 
1980). In the first re-examination in 1998, participants scoring 24 or less in the MMSE 
were referred to clinical phase. In the second re-examination in 2005-2008, screening 
criteria were modified to improve sensitivity to detect MCI and mild forms of 
dementia: 1) MMSE 24 points or less, 2) decline in MMSE of three or more points 
since the first re-examination, 3) delayed recall word list test <70% in the Finnish 
version of CERAD test battery, or 4) report of cognitive decline by the informant.  
    The clinical phase included a detailed cardiovascular and neurological 
examination performed by the study physician, and comprehensive cognitive testing 
by the study neuropsychologist. Participants judged to have possible dementia were 
referred to the differential diagnostic phase which included blood tests, chest 
radiograph, electrocardiogram, brain MRI or CT, and CSF analysis if needed. All 
available information was evaluated by a review board consisting of a senior 
neurologist, senior neuropsychologist, study physician and study 
neuropsychologist, and the final diagnosis was established.  
    Dementia was diagnosed according to the DSM-IV criteria (American Psychiatric 
Association, 1994), and AD according to the NINCDS-ADRDA criteria (McKhann et 
al., 1984). All individuals diagnosed with AD showed general and/or medial 
temporal lobe atrophy and no significant vascular pathology was observed on 
MRI/CT. Isolated, minor lacunar infarcts or moderate WML were not considered as 
exclusion criteria. Patients with AD scored four points or less on the Hachinski 
Ischemia Scale (Hachinski et al., 1975). The NINDS-AIREN criteria were used to 
diagnose VaD (Roman et al., 1993). Consensus criteria were used for diagnosing 
frontotemporal dementia (Neary et al., 1998), dementia with Lewy bodies (McKeith 
et al., 1996) and alcohol-related dementia (Oslin et al., 1998). A modified version of 
the Mayo Clinic Alzheimer’s Disease Research Center criteria was used to identify 
MCI (Petersen et al., 1995): 1) memory complaint by patient, family, or physician, 2) 
normal activities of daily living, 3) normal global cognitive function, 4) objective 
impairment of memory or other areas of cognitive functioning as evidenced by 
scores >1.5 standard deviations (SD) below the age-appropriate mean, 5) Clinical 
Dementia Rating (CDR) score of 0.5, and 6) absence of dementia. 
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4.4 ASSESSMENT OF VASCULAR FACTORS AND CONDITIONS 
4.4.1 Baseline (midlife) examination  
Survey methods used during the baseline visit were standardized according to 
international recommendations. They followed the WHO MONICA protocol in 1982 
and 1987, and were comparable with the methods used in 1972 and 1977 (Kuulasmaa 
et al., 2000). The baseline surveys included a self-administered questionnaire on 
health behaviors, health status and medical history. The questionnaire was mailed to 
the participants prior to their visit and a trained nurse checked that the 
questionnaire was fully completed. BP was measured from subject’s right arm after 
they had been seated for five minutes. A non-fasting venous blood specimen was 
taken to determine the serum cholesterol level. Serum cholesterol concentrations 
were measured in the years 1972 and 1977 from frozen serum using Lieberman-
Burchard method. Instead, in 1982 and 1987 serum cholesterol concentrations were 
measured from fresh serum using the enzymatic cholesterol oxidase/p-
aminophenazone (CHOD-PAP) method. There was a systematic difference (2.4%) 
between cholesterol measurement methods, and because of that, the results were 
corrected accordingly (Sundvall et al., 2007). All cholesterol levels were determined 
in the same central laboratory and the laboratory data were standardized with the 
national and international reference laboratories. Participants’ height (m) and weight 
(kg) were measured and BMI was calculated (kg/m2). 
4.4.2 First and second CAIDE re-examinations  
Survey methods used during the first and second re-examinations were identical to 
those used during the midlife visit in all major aspects. In addition to the midlife 
self-administered questionnaire, drug use and psychosocial factors were enquired. 
The APOE-genotypes were assessed from blood leucocytes using polymerase chain 
reaction and HhaI digestion (Tsukamoto et al., 1993).  
4.4.3 Coronary heart disease diagnosis in the Finnish Hospital Discharge Register 
The Finnish Hospital Discharge Register is maintained by the National Institute for 
Health and Welfare. This includes information on in-patient stays in public hospitals 
(i.e. main reason of hospitalization; other diseases/conditions are recorded to a lesser 
extent) starting from 1969. Information from out-patient clinics, health centers or 
private hospitals is not included. Diagnoses are based on ICD-codes. ICD-8 was used 
in Finland during 1969-1986, ICD-9 during 1987-1995, and ICD-10 from 1996 
onwards. The identification of the persons in the register is based on the unique 
identification code, which is given to every resident in Finland. CHD diagnoses were 
obtained using the following ICD codes: 410-414 (ICD-8); 410-414 (ICD-9); I20-I25 
(ICD-10). 
4.4.4 CAIDE Dementia Risk Score  
The midlife CAIDE Dementia Risk Score for each participant was calculated 
according to previously specified cut-offs and number of points (Table 4) (Kivipelto 
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et al., 2006). Two versions of the CAIDE risk score were calculated based on the 
initial publication: basic model including age, gender, education, SBP, total 
cholesterol, BMI and leisure-time physical activity (range 0-15 points); and APOE 
model additionally including APOE4 carrier status (range 0-18 points). Assessment 
of the factors used in CAIDE Dementia Risk Score is described in 4.4.1 and 4.4.2. 
Physical activity was assessed with the question: ‘How often do you participate in 
leisure-time physical activity that lasts at least 20-30 minutes and causes 
breathlessness and sweating?’ Response options were: 1) daily; 2) 2-3 times a week; 
3) once a week; 4) 2-3 times a month; 5) a few times a year; and 6) not at all. 
Participants who engaged in physical activity at least twice a week (options 1 or 2) 
were regarded as active, and the others as inactive. 
 
Table 4. CAIDE Dementia Risk Score factors and number of points 
 Model 1  
(without APOE) 
Model 2 
(with APOE) 
Age 
  <47 years 
  47-53 years 
  >53 years 
 
0 
3 
4 
 
0 
3 
5 
Education 
  	
 
  7-9 years 
  0-6 years 
 
0 
2 
3 
 
0 
3 
4 
Sex 
  Women 
  Men 
 
0 
1 
 
0 
1 
Systolic blood pressure 
   
  >140 mmHg 
 
0 
2 
 
0 
2 
Body-mass index 
  2 
  >30 kg/m2 
 
0 
2 
 
0 
2 
Total cholesterol 
   
  >6.5 mmol/l 
 
0 
2 
 
0 
1 
Physical activity 
  Active 
  Inactive 
 
0 
1 
 
0 
1 
	

	 
  Non-carrier 
  Carrier 
 
- 
- 
 
0 
2 
Total number of points Max. 15 points Max. 18 points 
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4.5 STATISTICAL ANALYSES 
4.5.1 Study I 
Study I included the CAIDE MRI population from the first re-examination (n=112). 
The focus was on midlife BP, BMI and total cholesterol, their changes from midlife to 
the first re-examination, and APOE genotype in relation to WML at the first re-
examination. The distribution of the subjects with dementia (n=39), and age- and sex-
matched MCI (n=31) or controls (n=42) did not match the distribution in the original 
CAIDE population. In order to ensure representativeness, the data was weighted for 
the inverse of the probability of each person from the original CAIDE population to 
be included in the 1998 MRI population. 
    Participants were categorized according to the total WML score as follows: 
no/mild WML (	-7 points) and severe WML ( 8 points). 
2-test and ordinal regression analyses were used to calculate p-values for the 
descriptive statistical differences between WML groups. Ordinal regression analyses 
were also used for calculating odds ratios (OR) and 95% confidence intervals (CI) for 
the associations between BP, BMI, total serum cholesterol, APOE and WML. As 
WML are common findings in the elderly, ORs cannot be used meaningfully as an 
estimate for risk. Therefore, the risk ratios (RR) were calculated from the ORs using a 
previously published formula which better represents the true relative risk (Zhang 
and Yu, 1998). The original formula was modified to fit the model with trichotomous 
outcome as a dependent variable.  
    The participants with SBP "	
 #" $&		
hypertensive. Subjects with BMI 25-30 were considered as overweight, and those 
with BMI 30 kg/m2 or more were classified as obese. The cut-off for high total 
cholesterol was considered to be 6.5 mmol/l, because of the generally high serum 
total cholesterol values in the study population. APOE4 carriers were categorised as 
heterozygous (one APOE 4 allele) and homozygous (both APOE 4 alleles). 
Analyses were adjusted for socio-demographic factors including sex, age, education 
and follow-up time, and also self-reported antihypertensive treatment (hypertension 
analyses) and lipid-lowering treatment (cholesterol analyses) (model 1). Additional 
adjustments were done for the diagnosis of dementia/MCI, APOE carrier status, self-
reported smoking and alcohol use and vascular factors (SBP, DBP and cholesterol in 
BMI analyses; cholesterol and BMI in hypertension analyses; and SBP, DBP and BMI 
in cholesterol analyses) (model 2). The level of significance was p<0.05 in all 
analyses. All statistical analyses were done using SPSS 17.0. 
 
4.5.2 Study II 
Study II included 63 individuals without dementia from the CAIDE MRI population 
in the second re-examination. These participants had MRIs of adequate quality to 
permit cortical thickness measurements. Suitability of MRIs for cortical thickness 
analyses was evaluated visually based on successfulness of registration and 
segmentation and also for the presence of artifacts. MRIs were graded from 0 to 3 
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(0=very suitable, 3=not suitable) and all MRIs graded as 3 (n=7) were excluded. Data 
weighting could not be used in the CAIDE 2005-2008 MRI population to ensure 
representativeness for the original CAIDE population. Subjects with dementia (n=37) 
were excluded from the study, and analyses were focused on elderly subjects at risk 
of dementia.   
    Study II focused on midlife BP, BMI, total cholesterol, their changes from midlife 
to the second re-examination, and APOE genotype in relation to cortical thickness in 
the second re-examination. Statistical analyses were conducted in two steps. First, in-
house scripts under Matlab R2008a (Mathworks Inc., Natick, Mass., USA) were used 
to identify brain regions significantly related to BP, BMI or cholesterol. The regions 
were identified based on group level analyses (significant differences in cortical 
thickness between subjects with midlife hypertension/controls; midlife 
overweight/controls; and hypercholesterolemia/controls) using a whole brain 
cortical thickness analysis method. Midlife hypertension was defined as SBP 
mmHg and/or DBP #5 mmHg, overweight as BMI 25, and hypercholesterolemia as 
total cholesterol 7 mmol/L. The analyses were adjusted for age, sex, follow-up time, 
scanner type, antihypertensive treatment (in BP analyses), and lipid-lowering 
treatment (in cholesterol analyses). Information on BP- and cholesterol-lowering 
medication was obtained from the Drug Reimbursement Register in Finland. 
Parametric t-tests were performed for each vertex, and the results were corrected for 
multiple comparisons using the false discovery rate (FDR) technique (Genovese et 
al., 2002) (p<0.05). 
    In the second step of the analyses, mean cortical thickness was calculated for each 
selected brain region (the minimum size for a region to be selected was 50 nodes), 
and the absolute mean thickness value for each subject was exported to SPSS 19.0 
(SPSS Inc., Chicago, IL, USA) for more detailed analyses. Since only hypertension 
was significantly associated with cortical thickness in the first step, the second step 
of statistical analyses focused on BP and related brain regions. Linear regression 
analyses were performed to investigate the links between midlife SBP, DBP and PP 
values and late-life cortical thickness (distribution of cortical thickness values was 
normalized with logarithmic transformations). General linear models for repeated 
measures were used for studying the relations between changes in SBP, DBP and PP 
from midlife to late-life and the cortical thickness in late-life. For each chosen brain 
area, cortical thickness values were categorized into two groups (lower versus 
higher) using the mean value as the cutoff. Analyses were adjusted for age, sex, 
follow-up time, scanner type, antihypertensive treatment and cardio/cerebrovascular 
conditions (self-reported myocardial infarction, heart failure, diabetes, or 
stroke/transient ischemic attack). Subjects’ characteristics were also analysed with 
SPSS software using 2 for categorical variables and Student’s t-test for continuous 
variables. The level of significance was set to p<0.05 in all analyses.   
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4.5.3 Study III 
Study III included 69 individuals without dementia from the CAIDE MRI population 
at the second re-examination: the 63 participants in Study II and 6 additional subjects 
who screened as positive but did not fulfill criteria for MCI or dementia. These 
participants had MRIs of adequate quality for cortical thickness measurements. 
Study III focused on associations between CHD from midlife to second re-
examination and cortical thickness, GM and WML volume at the second re-
examination. Possible modifying effects of BP were also investigated. 
    Statistical analyses were performed in two steps. Regional cortical thicknesses 
were identified based on group level analyses (significant differences in cortical 
thickness between subjects with or without CHD). The mean absolute cortical 
thickness of these regions was calculated (the minimum size for a region to be 
selected for more detailed analyses was 100 nodes) and exported to SPSS 19.0. In the 
second step, relations between CHD, BP, cortical thickness and GM and WML 
volumes were analysed with SPSS using linear regression. Subjects’ characteristics 
were analysed with SPSS software using 2 for categorical variables and Student’s t-
test for continuous variables.  
    Several definitions were used for CHD: all CHD diagnosed until the first CAIDE 
re-examination; all CHD diagnosed until the second re-examination; and CHD with 
shorter/longer duration. Duration of CHD was calculated as number of years 
between the first date of diagnosis and date of second CAIDE re-examination. 
Midlife hypertension was defined as SBP 	
 95 mmHg. All analyses 
were adjusted for age, sex, follow-up time and scanner type. Additionally, GM 
volume analyses were adjusted for TIV. WML volumes were log-transformed to 
normalize distribution. The results from linear regression analyses are presented as 
standardized -coefficients (p-values). The level of significance was set at p<0.05 in 
all analyses. 
4.5.4 Study IV 
Study IV included both CAIDE MRI populations from the first (n=112) and second 
(n=69) re-examinations. As in Study I, data from the first re-examination were 
weighted for the inverse of the probability of each person from the original CAIDE 
population to be included in the 1998 MRI population, in order to ensure 
representativeness. Study IV focused on associations between CAIDE Dementia Risk 
Score at midlife and cortical thickness, GM volume, WML volume, and visual 
ratings of WML and MTA on MRI at the first or second re-examination. 
    Statistical analyses were done using SPSS 19.0 (SPSS Inc., Chicago, IL, USA). The 
level of statistical significance was p<0.05 in all analyses. The CAIDE Dementia Risk 
Score at midlife was categorized as <10 points or @$X\^_`
and <11 points or @$X^_`{ 
    MRI outcomes in the first re-examination: The total WML visual rating score was 
categorized as no/mild WML (|		
@}{  The 
sum of left and right visual MTA ratings was calculated, and MTA was categorized 
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as no atrophy (0-1 points) and mild to severe atrophy (2-5 points). Logistic 
regression analyses were used to calculate ORs and 95% CIs for the associations 
between CAIDE Dementia Risk Score and WML and MTA ratings. Analyses were 
adjusted for follow-up time. Since WML and MTA are common at older ages, ORs 
cannot be used meaningfully as an estimate for risk. Therefore, RRs were calculated 
from ORs using a previously published formula which better represents the true 
relative risks (Zhang and Yu, 1998). Linear regression analyses were used for 
calculating standardized beta-coefficients () and p-values for the associations 
between CAIDE Dementia Risk Score and GM volume. The analyses were adjusted 
for follow-up time and TIV. 
    MRI outcomes in the second re-examination: The sum of left and right visual MTA 
ratings was calculated, and MTA was categorized as no atrophy (0-2 points) and 
mild to severe atrophy (3-5 points). The cut-off was increased to 3 points because 
MTA scores were generally higher compared to the first re-examination. Logistic 
regression was used to analyse the relation between CAIDE Dementia Risk Score 
and MTA (model adjusted for follow-up time and scanner type), and RR (95% CI) 
was calculated from OR (95% CI). WML volumes were log-transformed to normalize 
distribution, and linear regression was used to analyse associations between CAIDE 
Dementia Risk Score and WML volume (model adjusted for follow-up time and 
scanner type), or GM volume (model adjusted for follow-up time, scanner type and 
TIV). Relations between CAIDE Dementia Risk Score and regional cortical thickness 
were evaluated using in-house scripts under Matlab R2008a (Mathworks Inc., 
Natick, Mass., USA) as previously described. In the group level analyses, parametric 
t-tests were performed for each vertex, and results were corrected for multiple 
comparisons using the FDR technique (Genovese et al., 2002) (p<0.05). 
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5 Results 
 
5.1 CHARACTERISTICS OF THE CAIDE MRI POPULATIONS 
Sociodemographic and clinical characteristics of the two MRI populations in the first 
and second re-examination are shown in Table 5.  
Table 5. Characteristics of MRI populations in the 1st and 2nd CAIDE re-examinations 
Characteristics N 
MRI in 1st re-
examination 
(n=112) 
 
N 
MRI in 2nd re-
examination 
(n=69) 
Age in midlife, years (SD) 112 50.63 (5.14) 69 49.88 (6.02) 
Age in re-examination, years (SD) 112 72.85 (3.85) 69 77.89 (3.50) 
Sex (men), n (%) 112 40 (35.4) 69 27 (39.1) 
Education, years (SD) 110 7.29 (2.68) 67 7.79 (2.59) 
Total follow-up time, years (SD) 112 22.03 (3.22) 69 28.01 (4.75) 
Midlife SBP, mmHg (SD) 112 144.71 (20.67) 69 148.86 (24.79) 
Midlife BMI, kg/m2 (SD) 112 26.92 (3.63) 69 26.63 (4.20) 
Midlife cholesterol, mmol/l (SD) 112 7.18 (1.22) 69 7.05 (1.17) 
Midlife physical activity (active), n (%) 109 43 (39.4) 68 26 (38.2) 
APOE status (carrier), n (%) 105 41 (39.1) 57 22 (38.6) 
CAIDE Risk Score model 1, median (range) 107 9 (1-14) 66 9 (1-14) 
CAIDE Risk Score model 2, median (range) 99 10 (1-17) 56 10 (1-15) 
GM volume, ml (SD) 107 505.52 (47.93) 69 615.38 (71.16) 
TIV volume, ml (SD) 107 1380.51 (129.09) 69 1339.33 (143.64) 
WML volume, ml (SD) - - 69 32.93 (29.80) 
WML visual rating, median (range) 112 5 (0-22) - - 
MTA sum, median (range) 109 2 (0-5) 69 2 (0-6) 
Values are means (± SD) for continuous variables, medians (range) for ordinal variables and 
absolute numbers (%) for categorical variables. Values shown for the first re-examination are 
weighted. Factors included in the CAIDE Dementia Risk Score were measured in midlife; others are 
measured in the first or second re-examinations. 
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Sociodemographic and clinical characteristics of the weighted CAIDE 1998 MRI 
population according to severity of WML are shown in Table 6. 
Table 6. Sociodemographic and clinical characteristics of the weighted CAIDE MRI 
population in the first re-examination 
Characteristic 
(n=112) 
No/mild WML 
(n=52) 
Moderate WML 
(n=30) 
Severe WML 
(n=30) 
p-value 
Sex (men), % 34.6 43.3 26.7 0.399 
Age in late life, yrs 71.62 (3.44) 72.90 (4.16) 74.92 (3.40) 0.001 
Follow-up time, yrs 22.21 (2.93) 22.27 (3.95) 21.49 (2.91) 0.436 
Education, yrs 6.71 (2.02) 8.23 (2.42) 7.29 (3.57) 0.162 
Overweight, % 42.3 60.0 36.7 0.051 
Obesity, % 19.2 6.7 36.7 0.051 
Hypertension, % 53.8 40.0 73.3 0.033 
Hypercholesterolemia, % 69.2 70.0 71.0 0.986 
	!
"# 34.6 28.6 36.0 0.562 
!
"# 5.8 10.7 0.0 0.562 
Dementia, % 2.0 3.3 6.7 0.545 
MCI, % 3.8 6.7 6.7 0.804 
Smoking (yes), % 21.2 50.0 30.0 0.025 
Alcohol (yes), % 34.1 45.5 36.4 0.662 
$!
	'
+?@QZ	['\'!!
]	\^
'_`	['
+#QZ	[	\[]	\^
{2-test 
and ordinal regression were used to obtain p-value for the differences between the groups. 
Subjects with moderate and severe WML were older than the subjects with no/mild 
WML. Midlife hypertension and overweight/obesity were more frequent in 
participants with more severe WML. Smoking in midlife was more common in the 
moderate and severe WML groups compared to no/mild WML group. 
    Table 7 shows the sociodemographic and clinical characteristics of the CAIDE MRI 
population in the second re-examination (63 individuals included in Study II) 
according to midlife BP levels. Subjects with midlife hypertension tended to be older 
than subjects without hypertension, and their BMI was significantly higher. 
Although the group with midlife hypertension had higher BP levels at baseline, the 
differences were no longer significant at the first or second re-examinations. Mean 
SBP levels (SD) in the entire MRI population increased from 148.52 (25.71) mmHg at 
midlife to 159.58 (24.26) mmHg in the first re-examination, then decreased to 147.10 
(21.79) mmHg in the second re-examination. Mean DBP levels (SD) declined from 
90.38 (11.44) mmHg at midlife to 84.72 (11.21) mmHg in the first re-examination and 
74.92 (11.13) mmHg in the second re-examination. 
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Table 7. Population characteristics in the second re-examination according to the 
presence of midlife hypertension 
 
Characteristic Controls (n=40) Hypertensives (n=23) p-value 
Age in the 2nd re-examination, years 77.24 (3.43) 78.76 (3.18) 0.09 
Sex (men), % 40.0 34.8 0.68 
Education, years 8.21 (3.08) 7.13 (1.69) 0.13 
Follow-up time, years 27.65 (4.85) 28.53 (4.77) 0.49 
APOE carrier status, % 40.6 36.8 0.79 
SBP in midlife, mmHg 133.10 (12.47) 175.35 (20.12) <0.01 
SBP in the 1st re-examination*, mmHg 156.0 (22.47) 165.50 (26.47) 0.19 
SBP in the 2nd re-examination, mmHg 144.63 (20.42) 151.39 (23.86) 0.24 
DBP at midlife, mmHg 84.13 (6.89) 101.26 (9.49) <0.01 
DBP in the 1st re-examination*, mmHg 83.27 (10.95) 87.10 (11.49) 0.24 
DBP in the 2nd re-examination, mmHg 74.70 (9.59) 75.30 (13.62) 0.84 
Midlife BMI, kg/m2 25.75 (3.81) 28.69 (4.57) 0.01 
Midlife cholesterol, mmol 6.86 (0.97) 7.15 (1.35) 0.33 
MMSE in the 1st re-examination* 25.64 (2.22) 25.30 (2.32) 0.61 
MMSE in the 2nd re-examination 24.45 (2.28) 24.04 (2.29) 0.50 
Region of Interest, mean 
thickness** 
   
Left Anterior Insula 3.92 3.66 <0.01 
Right Anterior Insula 4.52 4.14 <0.01 
Left Orbitofrontal Area 3.47 3.18 <0.01 
Right Orbitofrontal Area 3.37 3.10 <0.01 
Left PSTG*** 3.16 2.90 <0.01 
Right PSTG*** 2.89 2.63 <0.01 
Left Intraparietal Sulcus 3.29 3.06 <0.01 
Right Temporal Pole 3.82 3.47 <0.01 
Right Entorhinal Cortex 3.58 3.19 <0.01 
Right Inferior Frontal Gyrus 3.20 2.95 <0.01 
$!
	'
+?@QZ	['\'!!
]	\^
'_`	['
Z	[	\[]	\^
{2 test and 
independent t-test were used to obtain p-values for characteristic differences. P-values<0.05 are 
bold. * There were 10 subjects who did not participate in the first re-examination in 1998-1999 (3 
hypertensives and 7 controls). ** Mean thicknesses (mm) were calculated for all areas that 
included over 50 nodes in t-statistical difference maps. Non-parametric Mann-Whitney U test was 
used to obtain p-value for the differences between the groups. *** PSTG = Posterior Superior 
Temporal Gyrus 
 
The value of mean BMI (SD) changed from 26.84 (4.31) kg/m2 in midlife to 29.06 
(5.49) kg/m2 in the first re-examination and 27.38 (4.71) kg/m2 in the second re-
examination. Mean cholesterol levels (SD) declined from 6.97 (1.12) mmol/l in 
midlife to 5.97 (1.21) mmol/l in the first re-examination, then to 5.16 (1.20) mmol/l in 
the second re-examination. 
    When the 63 subjects included in the 2005-2008 MRI population were compared to 
the rest of the individuals without dementia participating in the 2005-2008 
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differential diagnostic phase (n=108), similar patterns of change in SBP, DBP, BMI 
and cholesterol were observed. Significant differences between groups were 
observed only for DBP in 1998, with levels that were slightly lower (mean 81.00, SD 
10.93 mmHg) in the CAIDE participants not included in the 2005-2008 MRI 
population (p=0.04). 
    Sociodemographic and clinical characteristics of the CAIDE MRI population in the 
second re-examination (69 individuals) according to history of CHD diagnosed until 
the first re-examination are shown in Table 8. Of the 69 participants, 59 had also 
attended the first CAIDE re-examination in 1998 where 49 had been cognitively 
normal. In all, 27 subjects fulfilled the newly suggested criteria for MCI (combining 
clinical with MRI findings) (Frisoni and Coleman, 2011) at the time of the second re-
examination.  
Table 8. Population characteristics according to history of CHD diagnosed until the 1st 
CAIDE re-examination 
Characteristics no CHD (n=50) CHD (n=19) p-value 
Age in midlife (baseline), years 49.19 (6.21) 51.66 (5.18) 0.13 
Age in 1st re-examinationa, years 70.37 (3.41) 70.89 (3.55) 0.58 
Age in 2nd re-examination, years 77.78 (3.46) 78.40 (3.63) 0.51 
Sex (men), n (%) 16 (32.0) 11 (57.9) 0.05 
Follow-up time, years 28.59 (4.77) 26.75 (4.44) 0.15 
Education, years 7.51 (2.46) 8.44 (2.90) 0.19 
[		\	b, n (%) 17 (40.5) 5 (33.3) 0.65 
MMSE in the 1st re-examination 25.40 (2.10) 25.25 (2.70) 0.83 
MMSE in the 2nd re-examination 23.90 (2.30) 24.68 (2.26) 0.21 
Total GM volume, ml 617.21 (64.92) 610.54 (87.30) 0.73 
Total intracranial volume, ml 1326.24 (137.20) 1375.89 (156.12) 0.20 
Total WML volume, ml 31.79 (26.58) 36.23 (37.41) 0.81 
Region of interest, mean cortical  
thicknessc, mm 
  Left anterior insular cortex 4.37 (0.24) 4.06 (0.28) <0.01 
  Right anterior insular cortex 4.21 (0.24) 3.90 (0.32) <0.01 
  Left angular gyrus 3.18 (0.22) 2.90 (0.35) <0.01 
  Right angular gyrus 3.18 (0.20) 2.97 (0.32) <0.01 
  Left fusiform gyrus 3.62 (0.17) 3.42 (0.28) <0.01 
  Right fusiform gyrus 3.43 (0.18) 3.20 (0.23) <0.01 
  Left anterior prefrontal cortex 3.67 (0.23) 3.42 (0.29) <0.01 
  Right anterior prefrontal cortex 3.11 (0.25) 2.88 (0.33) <0.01 
  Left superior parietal gyrus 3.10 (0.23) 2.88 (0.29) <0.01 
  Left superior temporal gyrus 3.21 (0.16) 2.97 (0.33) <0.01 
  Right posterior middle frontal gyrus 3.06 (0.18) 2.82 (0.36) <0.01 
  Right orbitofrontal area 3.77 (0.24) 3.50 (0.39) <0.01 
  Right precentral gyrus 2.49 (0.22) 2.29 (0.24) <0.01 
  Right inferior frontal gyrus 3.02 (0.20) 2.78 (0.34) <0.01 
Values are means (standard deviations) for continuous variables and numbers (%) for categorical 
variables. P-values <0.05 are in bold font. a10 subjects did not participate in the 1st re-
examination; b APOE genotype information missing for 12 subjects; c Mean cortical thickness (mm) 
was calculated for all areas that included more than 100 nodes in t-statistical difference maps with 
a t-value over 3. 
     
49 
 
Only 3 participants had CHD at baseline (midlife), 19 at the time of the first CAIDE 
re-examination, and 26 at the second re-examination. Men tended to have CHD 
more often than women. No other significant differences were found between the 
groups with and without CHD. 
5.2 BLOOD PRESSURE, BMI, AND TOTAL CHOLESTEROL FROM 
MIDLIFE TO LATE-LIFE IN RELATION TO WML IN LATE-LIFE 
(STUDY I) 
Midlife hypertension was related to more severe WML 20 years later (RR 2.73; 95% 
CI 1.81-3.08), even after adjusting for age, sex, education, follow-up time, 
antihypertensive treatment, MCI/dementia diagnosis, APOE, smoking, alcohol use, 
total serum cholesterol, and BMI (Table 9). Further analysis revealed a significant 
relation between midlife DBP and late-life WML (RR 2.44; 95% CI 1.72-2.69).      
    People who were overweight (RR 2.53; 95% CI 1.70-2.89) or obese in midlife (RR 
2.94; 95% CI 2.44-3.02) were more likely to have more severe WML in late-life, even 
after all adjustments.  
Table 9. Midlife vascular factors and the risk of WML later in life 
 RR 95% CI 
Hypertension 
Model 1 
Model 2 
 
2.49 
2.73 
 
1.75-2.92 
1.81-3.08 
BMI 25-30 
Model 1 
Model 2 
BMI > 30 
Model 1 
Model 2 
 
1.65 
2.53 
 
2.52 
2.94 
 
0.98-2.27 
1.70-2.89 
 
1.71-2.88 
2.44-3.03 
Hypercholesterolemia 
Model 1 
Model 2 
 
1.17 
0.85 
 
0.66-1.72 
0.20-1.90 
APOE 4 heterozygous 
Model 1 
Model 2 
	 
Model 1 
Model 2 
 
0.85 
0.70 
 
1.31 
1.10 
 
0.45-1.40 
0.28-1.41 
 
0.39-2.26 
0.17-2.35 
 
Values are RR (95% CI) from ordinal regression analyses. Model 1 is adjusted for age, sex, 
education, and follow-up time (hypertension analyses are also controlled for antihypertensive 
treatment; hypercholesterolemia analyses are also controlled for lipid-lowering treatment). Model 
2 is additionally adjusted for diagnosis of dementia/MCI, APO[		\	
!
"\_\Z
\'g 
and alcohol and other midlife vascular factors (SBP, DBP, cholesterol, BMI). 
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Midlife hypercholesterolemia or APOE 4 carrier status showed no significant 
associations with late-life WML. In the cross-sectional analyses, only late-life 
overweight (RR 1.96; 95% CI 1.09-2.66) and obesity (RR 2.51; 95% CI 1.45-3.02) were 
related to WML after controlling for age, sex, education, MCI/dementia diagnosis, 
APOE, late-life smoking, alcohol use, cholesterol, SBP and DBP. 
    When changes in vascular risk factors over time were taken into account, 
hypertension was most consistently associated with more severe WML in late-life 
(Table 10). People with hypertension only in midlife, hypertension only in late-life, 
or hypertension during the entire study were more likely to have more pronounced 
WML as compared to people without hypertension (RR 3.25; 95% CI 2.46-3.41, RR 
2.91; 95% CI 1.10-3.39 and RR 3.14; 95% CI 1.83-3.40, respectively). Antihypertensive 
treatment was not related to WML (RR 1.11; 95% CI 0.38-1.97). 
    There was also an increased risk of more severe WML in participants with BMI 
over 25 in both midlife and late-life (RR 2.26; 95% CI 1.42-2.62) (Table 10). Being 
overweight or obese in midlife only was related to a higher risk of WML (RR 2.01; 
95% CI 0.71-2.62) than being overweight or obese in late-life only (RR 0.59; 95% CI 
0.11-1.76), although the results were not statistically significant.  
    No significant relationships were found between changes in cholesterol over time 
and WML. However, lipid-lowering treatment decreased the risk of having more 
severe WML in late-life (RR 0.13; 95% CI 0.02-0.59) after adjusting for age, sex, 
education, follow-up time, diagnosis of dementia/MCI, APOE, midlife smoking, 
alcohol use and vascular risk factors (SBP, DBP, cholesterol, BMI). A total of 23 
participants reported using cholesterol-lowering medication, 62 were non-users and 
there was no information about the remaining 27 subjects. 
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Table 10. Changes in vascular factors from midlife to late-life and their association with 
late-life WML 
Blood pressure Model 1 RR (95% CI) 
Model 2 
RR (95% CI) 
Midlife hypertension Late-life hypertension   
- - ref. ref. 
- + 2.01 (0.65-3.08) 2.91 (1.10-3.39) 
+ - 3.06 (2.35-3.33) 3.25 (2.46-3.41) 
+ + 2.92 (1.97-3.30) 3.14 (1.83-3.40) 
    
BMI   
Midlife > 25 Late-life > 25   
- - ref. ref. 
- + 1.12 (0.24-2.65) 0.59 (0.11-1.76) 
+ - 2.07 (0.68-3.16) 2.01 (0.71-2.62) 
+ + 2.18 (1.32-2.89) 2.26 (1.42-2.62) 
   
Serum total cholesterol   
Midlife 
hypercholesterolemia 
Late-life 
hypercholesterolemia 
  
- - ref. ref. 
- + --- --- 
+ - 1.34 (0.60-2.04) 1.03 (0.22-2.12) 
+ + 1.03 (0.37-1.87) 0.42 (0.05-1.67) 
 
Values are RR (95% CI) from ordinal regression analyses. + is present; - is absent.  
--- This category comprised only 2 subjects and could not be included in the analyses. 
Model 1 is adjusted for age, sex, education, and follow-up time (hypertension analyses are also 
controlled for antihypertensive treatment; hypercholesterolemia analyses are also controlled for 
lipid-lowering treatment). 
Model 2 is additionally adjusted for diagnoses of dementia/MCI, APO  [		\	 
!
" \_\Z
smoking and alcohol and other midlife vascular factors (cholesterol and BMI in hypertension 
analyses; SBP, DBP and cholesterol in BMI analyses; and SBP, DBP and BMI in cholesterol 
analyses). 
 
5.3 BLOOD PRESSURE, BMI AND TOTAL CHOLESTEROL FROM 
MIDLIFE TO LATE-LIFE IN RELATION TO CORTICAL THICKNESS IN 
LATE-LIFE (STUDY II) 
Differences in cortical thickness between participants with and without hypertension 
in midlife are shown in Figure 7. The hypertension group had significantly thinner 
cortex in the insular and orbitofrontal areas bilaterally, the right temporal pole, 
entorhinal cortex, inferior frontal gyrus, intraparietal sulcus and posterior superior 
temporal gyri bilaterally. Similar associations were seen when lowering the BP cut-
off value to 140/90 mmHg (21 controls vs. 42 hypertensives), but the differences were 
no longer significant. No differences in cortical thickness were found between 
cholesterol or BMI groups. Mean cortical thickness in the two brain regions closest to 
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statistical significance was 2.724 vs. 2.821 mm (medial occipital cortex) and 3.294 vs. 
3.446 mm (entorhinal cortex) in the overweight (n=42) vs. control (n=21) groups, 
respectively. With respect to the comparison between the hypercholesterolemia 
(n=30) vs. control (n=33) groups, mean cortical thickness was 3.530 vs. 3.526 mm 
(anterior cingulate cortex), and 3.886 vs. 3.946 mm (temporal pole), respectively. The 
presence of at least one APOE 4 allele was not related to cortical thickness in this 
population. 
 
Figure 7. T-statistical difference maps for midlife hypertensives versus controls (group 
analysis) corrected for false discovery rate (FDR). Significant (p<0.05) differences in 
cortical thickness between groups are displayed as color-labeled t-values on the surface 
of a standardized brain (warmer colors indicate thinner cortex). Analysis is adjusted for 
age, sex, follow-up time, scanner time and antihypertensive treatment. 
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In linear regression analyses, higher midlife SBP levels were associated with lower 
cortical thickness in the anterior insular cortex bilaterally, right posterior superior 
temporal gyrus, right temporal pole and right inferior frontal gyrus (Table 11). 
Higher midlife DBP was related to thinner cortex in the posterior superior temporal 
gyrus bilaterally and right entorhinal cortex. Midlife PP followed a similar pattern as 
midlife SBP. 
 
Table 11. Relations between midlife blood pressure values and late-life cortical thickness 
Late-life cortical 
thickness 
Midlife SBP 
}+`-value) 
Midlife DBP 
}+`-value) 
Midlife PP 
}+`-value) 
AIC left -0.38 (0.013) -0.24 (0.10) -0.35 (0.022) 
AIC right -0.50 (<0.01) -0.22 (0.11) -0.51 (<0.01) 
OFC left -0.28 (0.063) -0.19 (0.18) -0.24 (0.10) 
OFC right -0.22 (0.17) -0.28 (0.057) -0.10 (0.54) 
PSTG left -0.24 (0.095) -0.29 (0.031) -0.12 (0.39) 
PSTG right -0.28 (0.031) -0.24 (0.04) -0.20 (0.12) 
IPS left -0.13 (0.38) -0.07 (0.61) -0.13 (0.39) 
TP right -0.33 (0.032) -0.16 (0.28) -0.33 (0.029) 
EC right -0.31 (0.051) -0.31 (0.033) -0.19 (0.21) 
IFG right -0.33 (0.026) -0.23 (0.09) -0.28 (0.059) 
 
$!
 	 
'_	_\_ }-coefficients (p-values) from linear regression analyses with cortical 
thickness as outcome variable. All analyses are adjusted for age, sex, follow-up time, scanner 
type, antihypertensive treatment and cardio/cerebrovascular conditions (myocardial infarction or 
heart failure or diabetes or stroke/transient ischemic attack). P-values<0.05 are bold. 
AIC=Anterior Insular Cortex, OFC=Orbitofrontal Cortex, PSTG=Posterior Superior Temporal Gyrus, 
IPS=Intraparietal Sulcus, TP=Temporal Pole, EC=Entorhinal Cortex, IFG=Inferior Frontal Gyrus 
 
There was a continuous decline in SBP from midlife until the second re-examination 
in subjects with cortical thickness lower than the mean in right or left anterior insular 
cortex (Figure 8). A similar trend was seen for SBP and right posterior superior 
temporal gyrus. In participants with cortical thickness higher than the mean, the 
decline in SBP started at older ages. SBP in midlife was higher in the group with the 
thinner cortex as compared with the group with higher cortical thickness (p<0.05), 
but differences in SBP between the cortical thickness groups were not significant at 
older ages. No differences between patterns of association with cortical thickness 
were observed with respect to the DBP. A relatively uniform increase in PP after 
midlife was observed in subjects with late-life cortical thickness lower than the mean 
(Figure 8). Among subjects with cortical thickness higher than the mean, PP 
increased until the first follow-up and then decreased. This pattern was observed for 
anterior insular cortex on both sides and the right posterior superior temporal gyrus. 
PP in midlife was higher in the group with lower cortical thickness compared with 
the group with higher cortical thickness in these regions (p<0.05), but differences in 
PP between cortical thickness groups were not significant at older ages. 
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Figure 8. Changes in blood pressure from midlife to late-life in relation to cortical 
thickness at late-life. Y-axis shows the values of BP (SBP, DBP, PP); x-axis indicates the 
time of each BP measurement. The dotted line indicates changes in BP over time in 
people with cortical thickness lower than the mean. The continuous line indicates 
changes in BP over time in people with cortical thickness higher than the mean. Analyses 
are adjusted for age, sex, follow-up time, scanner type, antihypertensive treatment and 
cardio/cerebrovascular conditions (myocardial infarction or heart failure or diabetes or 
stroke/transient ischemic attack). P-values indicate if the patterns of BP changes are 
significantly different between persons with cortical thickness lower vs. higher than the 
mean in the second re-examination in 2005-2008. 
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5.4 CORONARY HEART DISEASE AND STRUCTURAL BRAIN 
CHANGES ON MRI (STUDY III) 
Compared to participants without CHD, those with CHD diagnosed until the first 
CAIDE re-examination had thinner cerebral cortex in multiple areas in the MRI scans 
in the second re-examination 7 years later (Figure 9). The thinner cortex was 
observed bilaterally in the anterior insular cortex, fusiform gyrus, anterior prefrontal 
cortex and angular gyrus; and additionally in the left superior termporal gyrus, left 
superior parietal gyrus, right orbitofrontal area, right precentral gyrus, right 
posterior middle frontal gyrus and right inferior frontal gyrus. After additionally 
adjusting for midlife SBP, only three areas displayed significant differences: right 
posterior middle frontal gyrus, inferior temporal gyrus and fusiform gyrus. When all 
CHD diagnoses until the second re-examination were taken into account, a similar 
but non-significant relation was found between cortical thickness and CHD (results 
not shown). Stratification of analyses according to APOE genotype did not change 
the results. 
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Figure 9. Statistical difference (t-value) maps of cortical thickness between CHD and 
control groups. Significant and FDR corrected (p<0.05) differences in cortical thickness 
between groups are displayed as color-labeled t-values on the surface of a standardized 
brain (warmer colors indicate thinner cortex). Analyses are adjusted for age, sex, follow-
up time and scanner type. 
Subjects with CHD diagnosed until the first or the second CAIDE re-examination 
had lower GM volume in the second re-examination: standardized -coefficients (p-
values) were -0.150 (0.018) and -0.129 (0.041), respectively. No significant 
associations between CHD diagnosed until the first or the second CAIDE re-
examination and WML volume were found: standardized -coefficients (p-values) 
were -0.046 (0.719), and 0.054 (0.670). When duration of CHD was taken into 
account, the associations with lower cortical thickness and GM volume were 
consistently significant in the group with the longer disease duration (Table 12). 
CHD was associated with lower cortical thickness in right anterior insular cortex and 
left fusiform gyrus irrespective of disease duration. 
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Table 12. Associations between CHD and cortical thickness, GM volume and WML volume 
according to the duration of CHD 
MRI measurements CHD duration 10 years CHD duration >10 years 
Mean cortical thickness   
 Left anterior insular cortex -0.170 (0.139) -0.499 (<0.001) 
 Right anterior insular cortex -0.311 (0.007) -0.452 (<0.001) 
 Left angular gyrus -0.075 (0.512) -0.464 (<0.001) 
 Right angular gyrus -0.165 (0.138) -0.417 (<0.001) 
 Left fusiform gyrus -0.273 (0.028) -0.385 (0.002) 
 Right fusiform gyrus -0.204 (0.094) -0.458 (<0.001) 
 Left anterior prefrontal cortex -0.098 (0.407) -0.401 (0.001) 
 Right anterior prefrontal cortex -0.185 (0.128) -0.379 (0.002) 
 Left superior parietal gyrus -0.163 (0.174) -0.384 (0.002) 
 Left superior temporal gyrus -0.153 (0.216) -0.340 (0.007) 
 Right posterior middle frontal gyrus -0.193 (0.075) -0.481 (<0.001) 
 Right orbitofrontal area -0.046 (0.714) -0.338 (0.008) 
 Right precentral gyrus -0.167 (0.160) 0.435 (<0.001) 
 Right inferior frontal gyrus -0.172 (0.134) -0.413 (0.001) 
Total GM volume 0.002 (0.972) -0.191 (0.002) 
Total WML volume 0.207 (0.100) -0.090 (0.470) 
 
$!
	
'_	_\_}-coefficients (p-values) from linear regression analyses.  
All analyses are adjusted for age, sex, follow-up time and scanner type. GM volume analyses are 
additionally adjusted for TIV.  
P-values <0.05 are bold. 
Table 13 shows the effects of midlife hypertension and changes in SBP from midlife 
to the second re-examination on the associations between CHD and MRI 
measurements. The strongest relationship between CHD diagnosed until first re-
examination and thinner cortex or lower GM volume in the second re-examination 
conducted 7 years later were found in participants with both CHD and midlife 
hypertension. Having CHD without midlife hypertension was also related to a 
reduced cortical thickness in some regions, but the associations were weaker. In 
participants without CHD but with midlife hypertension, total WML volume tended 
to be higher compared to participants with no CHD and no midlife hypertension. 
Subjects with CHD and whose SBP declined between midlife and second follow-up 
had significantly thinner cortex and lower GM volume compared to subjects with no 
CHD and stable SBP levels. CHD was related to a thinner cortex in some of the 
regions of interest even in participants with stable/increasing SBP, although the 
associations were weaker. A similar pattern of association was found for CHD and 
changes in DBP from midlife to late-life in relation to cortical thickness and GM 
volume in late-life. The relationship between CHD and MRI measurements was not 
influenced by other possible co-morbidities such as obesity and 
hypercholesterolemia (results not shown). 
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5.5 CAIDE DEMENTIA RISK SCORE AND STRUCTURAL BRAIN 
CHANGES ON MRI (STUDY IV) 
Table 14 shows the associations between CAIDE Dementia Risk Score in midlife and 
MRI measurements in the first re-examination. A higher CAIDE Dementia Risk 
Score was associated with increased risk of having more severe WML 20 years later: 
RR (95% CI) was 1.69 (1.15-2.08) for the version without APOE, and 1.27 (1.00-1.67) 
for the version with APOE. No significant associations were found with MTA score 
and GM volume. 
Table 14. Midlife CAIDE Dementia Risk Score and WML, MTA score and GM volume on 
MRI in the 1st CAIDE re-examination 
 
 
WML  
(visual rating) 
MTA score  
(visual rating) GM volume 
RR (95% CI) RR (95% CI) 	
-coefficient  (p-value) 
CAIDE Risk Score 
 <10 points (n=65) 
 `\'
+'Q 
 
ref. 
1.69 (1.15-2.08) 
 
ref. 
1.04 (0.69-1.33) 
 
ref. 
-0.03 (0.614) 
CAIDE Risk Score 
including APOE 
 <11 points (n=57) 
 `\'
+'Q 
 
 
ref. 
1.27 (1.00-1.67) 
 
 
ref. 
1.42 (0.79-2.03) 
 
 
ref. 
-0.06 (0.399) 
?'_	_\_ }-coefficients (p-values) are from linear regression analyses with GM volume as 
dependent variable. RRs (95% CIs) are from binary logistic regression analyses with WML or MTA 
score as dependent variable. Analyses are adjusted for follow-up time; GM volume analyses are 
additionally adjusted for TIV. 
Table 15 shows the relations between CAIDE Dementia Risk Score and MRI 
measurements in the second re-examination. A risk score above 10 points (version 
without APOE) was related to higher WML volume (standardized  coefficient 0.27; 
p-value 0.036), and more severe MTA 28 years later (RR 1.91; 95% CI 1.16-2.34). 
These associations were not significant for the risk score version including APOE 
genotype. No relationship was found with GM volume. 
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Table 15. Midlife CAIDE Dementia Risk Score and WML volume, MTA score and GM 
volume on MRI in the 2nd CAIDE re-examination 
 
WML volume MTA score  (visual rating) GM volume 
	
-coefficient 
(p-value) RR (95% CI) 
	
-coefficient 
(p-value) 
CAIDE Risk Score 
 <10 points (n=41) 
 `\'
+'Q 
 
ref. 
0.27 (0.036) 
 
ref. 
1.91 (1.16-2.34) 
 
ref. 
0.01 (0.885) 
CAIDE Risk Score 
including APOE 
 <11 points (n=31) 
 `\'
+'Q 
 
 
ref. 
0.21 (0.142) 
 
 
ref. 
1.44 (0.76-1.98) 
 
 
ref. 
-0.04 (0.562) 
?'_	_\_}-coefficients (p-values) are from linear regression analyses with WML volume or GM 
volume as dependent variables. RRs (95% CIs) are from binary logistic regression analyses with 
MTA score as dependent variable. Analyses are adjusted for total follow-up time and scanner type; 
GM volume analyses are additionally adjusted for TIV. 
Comparisons of regional cortical thickness between CAIDE Dementia Risk Score 
groups did not pass FDR-correction (p-value<0.05), but uncorrected results (t-values 
from 2.5 to 3.6) suggested decreased thickness in medial temporal lobe bilaterally, 
right insular cortex, posterior superior temporal gyrus, and posterior cingulate gyrus 
in those individuals with a higher dementia risk score (results not shown). 
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6 Discussion 
 
6.1 MIDLIFE BLOOD PRESSURE AND LATE-LIFE STRUCTURAL 
BRAIN CHANGES ON MRI  
The finding of an association between midlife hypertension and more severe WML 
20 years later in the CAIDE study is in line with previous longitudinal studies 
showing midlife hypertension as a risk factor for WML (Carmelli et al., 1999, de 
Leeuw et al., 1999, DeCarli et al., 1999a, Swan et al., 1998), and studies reporting 
increased WML progression in people with hypertension (Schmidt et al., 1999, 
Verhaaren et al., 2013). 
    The long-term effects of midlife hypertension on cortical thickness have not been 
previously investigated. In the CAIDE MRI population, midlife hypertension was 
associated with a thinner cortex up to 30 years later in several brain regions. It was 
decided to use a fully automatic surface-based whole brain segmentation method 
(Lerch and Evans, 2005) which enabled inspection of the cortex without any pre-
determined ROIs. It was particularly interesting that there was an association of 
midlife hypertension with the insular cortex bilaterally. The insular cortex plays a 
crucial role in BP regulation (Nagai et al., 2010), and it is also vulnerable to changes 
in BP and hypoperfusion due to its location in the region of the end arterioles of the 
middle cerebral artery. Autoregulation of brain arterioles can normally ensure that 
there is sufficient blood flow to the distal parts of brain tissue regardless of BP 
fluctuations (Strandgaard, 1976), but chronic hypertension combined with 
arteriosclerosis stiffens the arteriole walls and can compromise this mechanism 
(Feldstein, 2012).  
    CAIDE participants with hypertension also had a thinner cortex in the frontal and 
temporal lobe. This finding is in line with a recently published systematic review 
focusing on BP and brain atrophy (Beauchet et al., 2013). A previous study reported 
an association between elevated BP in midlife and lower hippocampal volume 25 
years later (Korf et al., 2004). Hypertension was not significantly related to cortical 
thickness in the parahippocampal gyrus in the CAIDE population, but right 
temporal lobe structures (temporal pole and entorhinal cortex) exhibited lower 
thickness in hypertensive individuals. These differences in results may be partly 
explained by the exclusion of images with poor cortical segmentation. It has been 
reported that automatic segmentation methods may have a tendency to perform 
poorly when there is severe medial temporal lobe atrophy (Chupin et al., 2009). 
    When analyzing SBP and DBP separately, only elevated midlife DBP was 
significantly associated with late-life WML in Study I. The relationship between 
midlife SBP and late-life cortical thickness was somewhat stronger than between 
midlife DBP and cortical thickness in Study II. Findings from earlier longitudinal 
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studies with over 10 year follow-up times have also been mixed. In the Honolulu-
Asia Aging Study (HAAS), high midlife SBP was associated with lower brain weight 
at autopsy in men (Petrovitch et al., 2000). In the same study, both midlife SBP and 
DBP were related to hippocampal atrophy as detected with MRI (Korf et al., 2004). 
Lower brain volume and increased WML volume were found in twin males with 
elevated midlife SBP and DBP in the National Heart, Lung and Blood Institute 
(NHLBI) study (Carmelli et al., 1999, DeCarli et al., 1999a, Swan et al., 1998). In the 
Rotterdam Scan Study, elevated DBP seemed to be more strongly related than SBP to 
late-life brain changes (de Leeuw et al., 1999, den Heijer et al., 2012, Heijer et al., 
2003). Variations in findings are even more apparent in studies with shorter follow-
up times (Beauchet et al., 2013). 
    The association between BP and brain atrophy is complex and influenced by 
several factors. BP levels vary with age, and for example the increase in SBP has been 
postulated to last longer than the increase in DBP levels due to large-artery stiffness 
(Franklin et al., 1997). Gender, antihypertensive treatment, definition of 
hypertension, follow-up time and brain volume/pathology assessment methods are 
all factors that influence the results. However, longitudinal cohort studies published 
so far emphasize that higher levels of SBP and/or DBP are related to greater brain 
volume reduction (Beauchet et al., 2013). GM atrophy has also been linked to WML, 
although the exact mechanisms are unknown (Appelman et al., 2009). Strategically 
situated WM changes might lead to deafferentation of connections between sub-
cortical and cortical structures and ultimately cause subsequent cortical atrophy. 
Also Wallerian degeneration (Waller, 1850) is one possible explanation, but 
histological verification of this theory is still lacking (Pantoni and Garcia, 1997). 
 
6.2 CHANGES IN BLOOD PRESSURE FROM MIDLIFE TO LATE-LIFE 
AND LATE-LIFE STRUCTURAL BRAIN CHANGES ON MRI 
 
Compared to participants without hypertension, those who developed hypertension 
later in life, and those with long-standing hypertension from midlife to late-life were 
more likely to have more severe WML. The strongest association with WML was 
seen for declining BP (hypertension in midlife but not in late-life). A similar relation 
between declining BP over a 20 year period and WML was reported in Rotterdam 
Scan Study; interestingly, this pattern was not observed in participants with shorter 
5-years of follow-up (de Leeuw et al., 1999). The Rotterdam Scan Study also 
indicated that DBP decreased from midlife to late-life in individuals with increased 
late-life brain atrophy (Heijer et al., 2003). 
    In the CAIDE study, declining SBP and increasing PP during three decades after 
midlife were associated with thinner cortex in brain areas involved in BP regulation 
(e.g. insula). SBP also decreased in subjects with thicker cortex, but it started later as 
compared to subjects with thinner cortex. This may be due to a bidirectional 
relationship between BP and brain changes: midlife hypertension increases the risk 
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of cerebrovascular or Alzheimer lesions/atrophy in the insular cortex, and once such 
lesions occur, they may affect BP regulation and lead to a decline in BP. In a previous 
study, subjects with elevated casual BP in 24-h ambulatory measurements had more 
insular subcortical hyperintensities as compared to controls (Goldstein et al., 2005). 
In autopsy studies, increased intracerebral accumulation of AD pathology was found 
in individuals with midlife hypertension (Petrovitch et al., 2000), and NFT pathology 
has been reported to affect insular cortex already in the preclinical phase of AD 
(Braak et al., 1998). The CAIDE 2005-2008 MRI population consisted of elderly 
subjects at-risk of dementia, and a pattern of decline in BP has been described in the 
years before the onset of dementia (Qiu et al., 2009). Declining BP and increased PP 
in midlife may also be related to cardiovascular diseases (Banach and Aronow, 
2012), which are risk factors for dementia and cognitive impairment (Bunch et al., 
2010, Qiu et al., 2006, Ross et al., 1999). However, adjustments for cardiovascular 
conditions and antihypertensive treatment did not change the results in Study II, 
suggesting that the BP decline may be related to lower cortical thickness 
independently of these other cardiovascular factors. 
     
6.3 BMI FROM MIDLIFE TO LATE-LIFE AND LATE-LIFE 
STRUCTURAL BRAIN CHANGES ON MRI 
 
Both obesity (BMI >30 kg/m2) and overweight (BMI 25-30 kg/m2) in midlife increased 
the risk of more severe WML two decades later in the CAIDE MRI population. A 
previous longitudinal study focusing on older people reported that every increase in 
BMI of 1.0 at age 70 doubled the risk of WML approximately 18 years later in elderly 
women (Gustafson et al., 2004). Other cross-sectional studies in middle-aged 
individuals have linked adiposity to WM pathology (Gazdzinski et al., 2008, 
Yamashiro et al., 2014). Signs of myelin damage were also reported in younger 
people who were overweight (Mueller et al., 2011, Verstynen et al., 2012). However, 
these studies had small sample sizes and no adjustments were made for BP. Cross-
sectional findings from the Framingham study have indicated that there is a relation 
between increased SBP and decreased WM integrity already in early midlife 
(Maillard et al., 2012), and BP levels need to be taken into account.  
    Midlife adiposity has been related to increased dementia risk (Kivipelto et al., 
2005, Whitmer et al., 2005a). As with BP, there is also a pattern of decline in BMI over 
time in individuals who will develop dementia later (Atti et al., 2008, Nourhashemi 
et al., 2003). In Study I, reduction in BMI values after midlife tended to relate to more 
severe WML in late-life, although the association was not statistically significant. 
However, elevated BMI during 20 years from midlife significantly increased the risk 
of more severe WML. 
    Individuals who are overweight/obese tend to have other comorbidities such as 
hypertension, hypercholesterolemia or diabetes, making it more difficult to study the 
independent effect of a single risk factor. Adiposity has been speculated to increase 
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the level of inflammation (Trayhurn and Wood, 2005), and levels of C-reactive 
protein have been associated with more severe and progressive WML in elderly 
people (van Dijk et al., 2005). A recent cross-sectional DTI-study indicated that the 
link between adiposity and white matter integrity is at least partly mediated via 
inflammation-related processes (Bettcher et al., 2013). Obesity has also been reported 
to exert an independent effect on carotid artery wall thickening in middle aged 
women (De Michele et al., 2002), which may lead to effects on the progression of 
cerebral arteriolosclerosis. Obstructive sleep apnea (OSA) is a frequent comorbidity 
accompanying adiposity, and OSA-induced night-time hypoxia, hypercapnia and 
transient hypertension episodes may be detrimental to the brain. Previous studies 
have related OSA to an increased risk of cognitive impairment and dementia (Yaffe 
et al., 2011), and also to GM and WM changes (Macey et al., 2002, Macey et al., 2008, 
Morrell et al., 2003). 
 
6.4 CHOLESTEROL FROM MIDLIFE TO LATE-LIFE AND LATE-LIFE 
STRUCTURAL BRAIN CHANGES ON MRI 
In the CAIDE 1998 MRI population, lipid-lowering drugs seemed to be protective 
against more severe WML. However, serum total cholesterol levels were not 
associated with WML or cortical thickness. Theoretically, hypercholesterolemia-
induced atherosclerosis could affect cerebral arterioles, leading to GM and WM 
changes. Cholesterol levels have also been associated with Alzheimer pathology 
(Björkhem et al., 2009, Launer et al., 2001. However, previous studies focusing on 
serum cholesterol levels and GM or WM changes have produced conflicting results 
(den Heijer et al., 2005a, Koschack et al., 2009, Leritz et al., 2011, Wolf et al., 2004). 
Only total serum cholesterol levels were measured at midlife in the CAIDE study. 
Guidelines for the prevention and treatment of CHD and ischemic stroke emphasize 
the importance of LDL and HDL in the development of atherosclerosis (Catapano et 
al., 2011). The levels of LDL- and HDL-cholesterol will also need to be taken into 
account when evaluating the effects of cholesterol on brain changes. 
 
6.5 CORONARY HEART DISEASE AND STRUCTURAL BRAIN 
CHANGES 
CHD was associated with decreased cortical thickness and lower total GM volume, 
and this relation was particularly strong for CHD with a longer duration (at least 10 
years). A previous cross-sectional study in male twins linked CHD to lower total GM 
volume (DeCarli et al., 1999b), but other studies have failed to detect this kind of 
association (Geerlings et al., 2010, Koschack and Irle, 2005, Manolio et al., 1994). The 
decline in brain volume observed in patients with CHD has been previously 
reported in regions related to AD such as temporal lobe, posterior cingulate and 
precuneus (Almeida et al., 2008, Koschack and Irle, 2005). In Study III, a similar 
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association between CHD and thinner cortex in parietal lobe structures was 
observed. Other regions related to cognitive functions, such as fusiform gyrus (Han 
et al., 2012, Tijms et al., 2013) and prefrontal cortex (Funahashi, 2001), also had a 
lower thickness in the CHD group. 
    Individuals with CHD often have other co-morbidities such as hypertension, 
hypercholesterolemia or other cardiovascular diseases. Similarly to CHD, 
hypertension-related brain changes are more frequently observed in the frontal lobe 
(Beauchet et al., 2013, Maillard et al., 2012). Cortical thinning and total GM volume 
loss were most evident in CAIDE participants with both CHD and midlife 
hypertension, pointing to a combined effect of these two factors. Furthermore, 
subjects with CHD and a declining SBP displayed more pronounced cortical 
thinning and lower total GM volume, a pattern similar to that observed in Study II. 
Declining BP values could also be a marker of left ventricular dysfunction, which can 
occur as a consequence of myocardial ischemia. Only four subjects with CHD had 
been diagnosed with heart failure in the CAIDE 2005-2008 MRI population, and 
adjusting the analyses for HF did not change the results. No quantitative measures 
of ventricular function (e.g. ejection fraction) were available, so milder forms of heart 
failure could not be identified. After adjusting for midlife hypertension in the 
analyses of the relationship between CHD and cortical thickness, some regions still 
showed significant associations, suggesting that the effects of CHD on the brain may 
be partly independent of BP. 
    Other cardiac diseases such as heart failure and atrial fibrillation may also increase 
the risk of dementia (Bunch et al., 2010, Miyasaka et al., 2007, Qiu et al., 2006). 
Studies of heart failure, atrial fibrillation and structural brain changes have reported 
less conflicting results in comparison to studies focusing on the relation between 
CHD and brain changes (Almeida et al., 2012, de Leeuw et al., 2000, Stefansdottir et 
al., 2013, Vogels et al., 2007). CHD and hypertension are both well known risk factors 
for heart failure and atrial fibrillation, which may in turn contribute to brain atrophy 
(Roman, 2004, Stefansdottir et al., 2013). These associations could not be studied in 
the CAIDE MRI populations due to the small number of participants with these 
distinct disorders (4 with heart failure and 5 with atrial fibrillation). 
    CHD diagnoses in the Finnish Hospital Discharge Register represent CHD severe 
enough to require hospitalization and there for milder forms of CHD could not be 
identified. In addition, people with severe CHD are less likely to survive to older 
ages, and thus the findings from Study III may actually underestimate the effects of 
CHD on the brain.     
    APOE 4 has been associated with higher risk of CHD (Bennet et al., 2007) and 
also with more severe coronary atherosclerosis (Kosunen et al., 1995). However, the 
APOE genotype did not influence the association between CHD and MRI 
measurements in Study III, possibly due to lack of statistical power. 
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6.6 CAIDE DEMENTIA RISK SCORE AND STRUCTURAL BRAIN 
CHANGES 
CAIDE Dementia Risk Score is a validated tool for estimating the 20 to 40 year 
dementia risk in the general population based on a midlife risk profile, but it was 
previously unclear if its dementia prediction ability relies more on cerebrovascular 
than on neurodegenerative pathology. A higher CAIDE Dementia Risk Score in 
midlife was associated with more severe WML 20 to 30 years later. An association 
with more pronounced MTA was observed in the population with longer follow-up 
times. Individuals with higher CAIDE Dementia Risk Score tended to have thinner 
cortex in several regions (e.g. posterior cingulate gyrus, temporal lobe, insular 
cortex), but these results did not remain after correction for multiple comparisons. 
There was no relation with total GM volume. 
    Since the risk score is based largely on vascular factors previously linked to WM 
and GM changes (Carmelli et al., 1999, de Leeuw et al., 1999, Gustafson et al., 2004, 
Gustafson et al., 2004, Korf et al., 2004, Soreca et al., 2009), it is not surprising that 
both more severe WML and MTA were found in individuals with higher midlife 
CAIDE Dementia Risk Score. Cerebrovascular lesions can be present in AD, 
especially at older ages, and they can lower the threshold for dementia 
(Neuropathology Group. Medical Research Council Cognitive Function and Aging 
Study, 2001, Snowdon et al., 1997). Hippocampal atrophy is a characteristic feature 
of AD (Burton et al., 2009), but it can also be present in VaD (Jack et al., 2002, Shiino 
et al., 2012, Yin et al., 2014). Previously, interactions between vascular and Alzheimer 
pathology have been described (Niwa et al., 2000, Thal et al., 2008). 
    A higher dementia risk score in midlife was associated with both visually rated 
WML in the first CAIDE re-examination and WML volume in the second re-
examination. Interestingly, more pronounced MTA was seen only in participants 
with higher risk scores in midlife and with longer follow-up times (i.e. second 
CAIDE re-examination). MTA is one of the diagnostic and early markers of AD 
(Dubois et al., 2007, Jack et al., 2013), and it has been pathologically characterized by 
an elevated NFT burden (Braak and Braak, 1991, Polvikoski et al., 2010). While WML 
may be common in the general population even at younger ages (Launer, 2004), 
MTA may take longer time to develop. The associations between midlife CAIDE 
Dementia Risk Score and cortical thickness in the second re-examination were not 
significant after correction for multiple comparisons, but it is worth noting that the 
principal identified regions (posterior cingulate gyrus, temporal lobe, and insular 
cortex) follow previously reported brain atrophy patterns in AD (Lerch et al., 2005). 
    In the initial publication, adding APOE 4 carrier status to the CAIDE Dementia 
Risk Score did not significantly improve the scale’s ability to predict dementia 
(Kivipelto et al., 2006). In Study IV, the risk score version including APOE was 
related to more severe visually rated WML in the first CAIDE re-examination, but 
not to the other MRI outcomes in the first or second re-examination. Since 
information about APOE genotype was not available for all participants, this may be 
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at least partly due to limited statistical power. Some previously postulated midlife 
risk factors for dementia such as diabetes mellitus, depressed mood, head trauma, 
central obesity, lung function or smoking are not included in the original CAIDE 
Dementia Risk Score, but in a recent study adding these factors into the analysis did 
not increase dementia prediction accuracy (Exalto et al., 2013). 
 
6.7 METHODOLOGICAL CONSIDERATIONS 
The four studies included in this thesis are based on data from the longitudinal 
population-based CAIDE study. CAIDE is one of the few studies with available 
detailed health-related information already at midlife, two re-examinations with 
total follow-up time of up to 30 years, and which has been specifically designed to 
investigate risk factors for dementia and AD. 
    One of the main limitations of Studies I-IV is the relatively small sample size, 
reducing their statistical power. This may have led to an underestimation or even a 
failure to observe the associations (type II error) between vascular risk 
factors/conditions and the MRI measurements. Small sample size also limited the 
possibility to do comprehensive stratified analyses based on participants’ cognitive 
status. The CAIDE MRI populations include selected individuals who participated in 
the first or second re-examination. In the CAIDE 1998 MRI population (39 
individuals with dementia, 31 with MCI and 42 controls, age- and sex-matched), 
data weighting was used to achieve representativeness with the original CAIDE 
sample. This was not possible in the 2005-2008 MRI population (37 dementia, 70 MCI 
and 6 controls). Instead, the analyses focused on participants at risk of dementia, and 
those already with dementia were excluded. Including a high proportion of people 
with dementia would have affected the results for two main reasons: manifest 
dementia involves rather pronounced brain changes, with the risk of 
misidentification/overestimation of associations with vascular factors; and 
pronounced brain abnormalities can also affect the quality of the automatic 
segmentation of MRIs. The 69 participants at risk of dementia in the 2005-2008 
CAIDE MRI population were not significantly different from the rest of the 
individuals in the original CAIDE population with respect to age at baseline (p=0.3), 
gender (p=0.8), education (p=0.2), midlife SBP (p=0.2) or DBP (p=0.6), total 
cholesterol (p=0.09), BMI (p=0.8), physical activity (p=0.4), APOE genotype (p=0.7), or 
CHD diagnosed during the study (p=0.4). 
    Although MRI was performed in both re-examinations, only 18 subjects had MRI 
from both time points. It was thus not possible to analyze changes in MRI 
measurements over time in relation to vascular factors. The MRI acquisition 
parameters and scanners were also different in the first and second re-examinations, 
limiting image analysis in some cases (e.g. WML volume and cortical thickness could 
not be measured reliably on some images from the first re-examination). 
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    Non-participation and survival bias may have also influenced the results. 
Individuals in the original CAIDE target population who died or did not participate 
in re-examinations had poorer health status and higher vascular risk (e.g. higher BP, 
BMI and cholesterol) compared to survivors/participants (Kulmala et al., 2014). This 
may have led to an underestimation of the effects of vascular risk factors on the 
brain. 
    Cognitive testing and MRI were not available at the baseline (midlife) visit. 
Alzheimer and cerebrovascular pathologies can start to develop long before any 
dementia diagnosis, and the possibility of reverse causality needs to be taken into 
account. However, if there were some individuals exhibiting the early stages of 
dementia (and more pronounced brain pathology) already at baseline, they would 
have been unlikely to survive and participate in re-examinations. Potential GM 
atrophy or WML in participants who later on developed dementia would nor have 
been anticipated to be severe enough to have a major influence on BP levels at 
midlife (Dickerson et al., 2011, Jack et al., 2013). 
    The CAIDE study provided a large amount of information about vascular and 
lifestyle-related factors, and analyses in Studies I-IV took into account several 
potential confounders and effect mediators. This is particularly important as 
vascular risk factors may affect the brain through shared pathways, and they can 
also interact with each other. However, the possibility of residual confounding 
cannot be fully excluded (e.g. less severe comorbid cardiovascular conditions who 
did not require hospitalization). 
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7 Conclusions 
 
Based on the findings from the present set of studies, the following conclusions can 
be drawn: 
1) Midlife hypertension was associated with an increased risk of more severe 
WML and lower cortical thickness 20 to 30 years later. Individuals with 
longstanding hypertension and those who developed hypertension at older 
ages also had an increased risk of WML. A decline in blood pressure from 
midlife to late-life was observed in subjects with thinner cortex in brain areas 
involved in blood pressure regulation (e.g. insular cortex). 
 
2) The presence of midlife overweight and obesity were related to an increased 
risk of more severe WML 20 years later. Elevated BMI from midlife to late-life 
was associated with WML in late-life.  
 
3) Although the serum total cholesterol level was not related to brain MRI 
measurements, lipid-lowering treatment seemed to exert a protective effect 
against WML. 
 
4) Lower total GM volume and reduced cortical thickness in several brain 
regions were found in subjects with coronary heart disease, particularly in 
those with a longer disease duration. This association was influenced by 
midlife blood pressure levels and changes in blood pressure over time. 
 
5) Higher midlife CAIDE Dementia Risk Score was associated with more severe 
WML and MTA 20 to 30 years later. 
The results of this project emphasize that vascular risk factors and conditions 
existing from midlife to older ages can influence the structural brain changes 
detected later with MRI. A longer exposure time to such factors is particularly 
detrimental. A validated, easy to use risk score for estimating dementia risk based on 
vascular factors can also point to an increased risk for cerebrovascular and 
neurodegenerative changes, and could be useful for identifying at-risk individuals 
who may benefit most from preventive interventions. 
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8 Future Perspectives 
 
Evidence from observational studies supports the hypothesis that there is an 
association between vascular risk factors already in midlife and late-life cognitive 
impairment, creating a window of opportunity for prevention. Interestingly, recent 
studies have hinted that the incidence of dementia may be indeed declining 
(Matthews et al., 2013, Qiu et al., 2013, Schrijvers et al., 2012). One possible 
explanation for this phenomenon is that there have been changes in cardiovascular 
risk factors since the 1960s-1970s, i.e. decreasing prevalence of hypertension, 
hyperlipidemia or smoking. However, both overweight and DM are becoming more 
common in middle-aged and older populations (Fielding et al., 2013, Finucane et al., 
2011, Luchsinger, 2010, Vartiainen et al., 2010). The midlife assessment of CAIDE 
participants took place during a time when the levels of many vascular risk factors 
were generally high throughout Eastern Finland (Puska et al., 1979). New 
epidemiological studies are needed to confirm the trend of declining dementia 
incidence, and also to investigate vascular risk factors in the new generations of 
older people, since it is clear that conditions in the population can change 
significantly during the time when long-term follow-up studies are on-going. It also 
remains to be determined whether changes in dementia incidence are accompanied 
by changes in the type and severity of brain pathology.  
    Although observational studies have indicated that treatment of vascular factors 
(e.g. antihypertensive treatment, lipid-lowering medication) may decrease the risk of 
dementia and slow cognitive decline (Chang-Quan et al., 2011, Deschaintre et al., 
2009, Luchsinger et al., 2007, Rockwood et al., 2002), these promising findings have 
not been easily translated into successful dementia prevention in randomized 
controlled trials (RCT) (Ligthart et al., 2010, Richard et al., 2012b). However, these 
RCTs were often add-on studies in trials focusing on decreasing cardiovascular 
mortality and preventing cardio- or cerebrovascular events. They also tended to 
include younger populations (<70 years), which resulted in a relatively low 
incidence of dementia and cognitive impairment, and thus they had a limited power 
to detect significant treatment effects (Ligthart et al., 2010). These methodological 
issues will need to be addressed in future prevention RCTs. 
    Future RCTs focusing on prevention of cognitive decline would be advised to 
include biomarkers for dementia-related diseases (e.g. MRI, PET or CSF markers) in 
order to better assess the overall effects of the intervention. Antihypertensive 
treatment has been postulated to exert a beneficial effect on WML progression in 
observational studies (Godin et al., 2011, Verhaaren et al., 2013), but no change in 
GM atrophy was seen in a 1-year follow-up study despite successful 
antihypertensive treatment (Jennings et al., 2011). In a 2-year RCT, statin therapy 
slowed the progression of WML in the group with severe WML already at baseline 
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compared to the control group (Mok et al., 2009), but these results have not been 
confirmed in other RCTs (ten Dam et al., 2005). 
    Late-life cognitive impairment is a heterogeneous condition and focusing only on 
treating a single risk factor may not be enough. RCTs targeting several risk factors 
simultaneously may be more likely to represent effective prevention strategies. Such 
multi-domain RCTs are already ongoing in several European countries, e.g. the 
European Dementia Prevention Initiative (EDPI, http://www.edpi.org) (Dehnel 2013, 
Richard et al., 2012). The EDPI includes three RCTs already in progress: in Finland, 
the Finnish Geriatric Intervention study to prevent cognitive impairment and 
disability (FINGER) (Kivipelto et al., 2013); in the Netherlands, the Prevention of 
Dementia by Intensive Vascular Care (preDIVA) trial (Richard et al., 2009); and in 
France, the Multidomain Alzheimer Prevention Trial (MAPT) (Carrié et al., 2012). 
Cognitive functioning or dementia are the primary outcomes in these trials, and they 
also include several neuroimaging exploratory outcomes: basic structural MRI 
modalities, and additionally DTI, FDG-PET for brain glucose metabolism, and PiB-
PET for brain amyloid are used in sub-groups in FINGER and MAPT. FINGER, 
MAPT and preDIVA have intervention periods of 2, 3 and 6 years, respectively, and 
planned follow-up periods of 7, 5 and 6 years (Richard et al., 2012a). Since brain 
changes on structural MRI and FDG-PET can be seen already years before 
AD/dementia (Jack et al., 2013), the results concerning the effects of vascular and 
lifestyle preventive interventions on these biomarkers will be of high interest. 
    A fourth trial, Healthy Aging Through Internet Counselling in the Elderly 
(HATICE) (http://www.hatice.eu/), focusing on management of vascular risk factors 
and conditions, is planned to start in 2015 in the Netherlands, Finland and France.  
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A 30-year Follow-up Study
Vascular risk factors and conditions 
have been associated with dementia 
and Alzheimer’s disease (AD), but the 
mechanisms are not fully understood. 
Because typical Alzheimer and 
cerebrovascular pathologies can 
develop long before dementia onset, 
a life-course perspective is needed to 
investigate risk factors. The present 
thesis focused on the effects of 
vascular risk factors and conditions 
during three decades from midlife 
to late-life on dementia-related 
structural brain changes on MRI in 
late-life.
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